

10/ 690,222

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal202txn

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	FEB 25	CA/CAPLUS - Russian Agency for Patents and Trademarks (ROSPATENT) added to list of core patent offices covered
NEWS	4	FEB 28	PATDPAFULL - New display fields provide for legal status data from INPADOC
NEWS	5	FEB 28	BABS - Current-awareness alerts (SDIs) available
NEWS	6	FEB 28	MEDLINE/LMEDLINE reloaded
NEWS	7	MAR 02	GBFULL: New full-text patent database on STN
NEWS	8	MAR 03	REGISTRY/ZREGISTRY - Sequence annotations enhanced
NEWS	9	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS	10	MAR 22	KOREAPAT now updated monthly; patent information enhanced
NEWS	11	MAR 22	Original IDE display format returns to REGISTRY/ZREGISTRY
NEWS	12	MAR 22	PATDPASPC - New patent database available
NEWS	13	MAR 22	REGISTRY/ZREGISTRY enhanced with experimental property tags
NEWS	14	APR 04	EPFULL enhanced with additional patent information and new fields
NEWS	15	APR 04	EMBASE - Database reloaded and enhanced
NEWS	16	APR 18	New CAS Information Use Policies available online
NEWS EXPRESS			JANUARY 10 CURRENT WINDOWS VERSION IS V7.01a, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 10 JANUARY 2005
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS INTER			General Internet Information
NEWS LOGIN			Welcome Banner and News Items
NEWS PHONE			Direct Dial and Telecommunication Network Access to STN
NEWS WWW			CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 15:04:38 ON 22 APR 2005

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 15:04:55 ON 22 APR 2005
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 21 APR 2005 HIGHEST RN 848979-49-7
 DICTIONARY FILE UPDATES: 21 APR 2005 HIGHEST RN 848979-49-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when
 conducting SmartSELECT searches.



```
*****
*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*
*****
```

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
 information enter HELP PROP at an arrow prompt in the file or refer
 to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10690222.str



chain nodes :
 10 12 13
 ring nodes :
 1 2 3 4 5 6 7 8 9
 ring/chain nodes :
 14
 chain bonds :
 4-10 7-13 8-12 13-14
 ring bonds :

10/ 690,222

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9

exact/norm bonds :

1-2 1-6 2-3 3-4 4-5 4-10 5-6 5-7 6-9 7-8 7-13 8-9 8-12 13-14

isolated ring systems :

containing 1 :

G1:C,N

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS


12:Atom 13:CLASS 14:CLASS

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 C,N

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sample

SAMPLE SEARCH INITIATED 15:05:23 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 49 TO ITERATE

100.0% PROCESSED 49 ITERATIONS

15 ANSWERS

SEARCH TIME: 00.00.02

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 560 TO 1400

PROJECTED ANSWERS: 68 TO 532

L2 15 SEA SSS SAM L1

=> s l1 ful

FULL SEARCH INITIATED 15:05:32 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 1036 TO ITERATE

100.0% PROCESSED 1036 ITERATIONS

290 ANSWERS

SEARCH TIME: 00.00.01

10/ 690,222

L3 290 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

161.33

161.54

FILE 'CAPLUS' ENTERED AT 15:05:38 ON 22 APR 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 22 Apr 2005 VOL 142 ISS 18

FILE LAST UPDATED: 21 Apr 2005 (20050421/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3 1- ibib abs hitstr

MISSING OPERATOR L3 1-

The search profile that was entered contains terms or nested terms that are not separated by a logical operator.

=> s l3

L4 15 L3

=> d his

(FILE 'HOME' ENTERED AT 15:04:38 ON 22 APR 2005)

FILE 'REGISTRY' ENTERED AT 15:04:55 ON 22 APR 2005

L1 STRUCTURE UPLOADED

L2 15 S L1 SAMPLE

L3 290 S L1 FUL

FILE 'CAPLUS' ENTERED AT 15:05:38 ON 22 APR 2005

L4 15 S L3

=> d l4 1- ibib abs hitstr

YOU HAVE REQUESTED DATA FROM 15 ANSWERS - CONTINUE? Y/(N):y


L4 ANSWER 1 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

ACCESSION NUMBER: 2004:898844 CAPLUS
DOCUMENT NUMBER: 141:379932

TITLE: Preparation of 4,7-dihydrothieno[2,3-b]pyridine and 5,8-dihydroimidazo[1,2-a]pyrimidine derivatives as antagonists of RFamide-related peptide (RFRP) receptor
INVENTOR(S): Ito, Fumio; Hinuma, Shuji; Kanazaki, Naoyuki; Cho, Nobuo; Yoshida, Hiromi; Matsumoto, Hirokazu
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 112 pp.
CODEN: JKKOAF

DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2004300147	A2	20041028	JP 2004-74929	20040316
PRIORITY APPLN. INFO:			JP 2003-72722	A 20030317
OTHER SOURCE(S):			MARPAT 141:379932	



AB Disclosed are RFamide-related peptide (RFRP)-binding G protein-coupled receptor (receptor OT7022) regulators containing the title compds. (I) [wherein ring A and B = (un)substituted aromatic ring; R1, R2, R3 = H, each (un)substituted hydrocarbyl or heterocyclyl, acyl; X = C, N; W = C, N; Y = Y = S, N, NH, O, CH, CH₂, N:CH, CH₂N] or salts or prodrugs thereof. Also disclosed are (1) analgesics, drugs for promoting the analgesic activity of other analgesics, or resistance-preventing drugs for other analgesics, (2) regulators for prolactin secretion, (3) inhibitors of pancreatic glucagon secretion, hypoglycemics, inhibitors of urine production, and (4) inhibitors of bladder contraction. Thereby, they are useful as preventives and/or remedies for (1) hyperprolactinemia, pituitary adenoma, interbrain (diencephalon) tumor, menstruation disorder, stress, autoimmune disease, prolactinoma, sterility, impotence, amenorrhea, galactorrhea, acromegaly, Chiari-Frommel syndrome, Argonz-del Castillo syndrome, Forbes-Albright syndrome, breast cancer lymphoma, Sheehan's syndrome, or spermatogenesis disorder, (2) diabetes, glucose tolerance disorder, ketonuria, acidosis, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, pollakiuria, enuresis, hyperlipidemia, sexual function disorder, skin disease, arthropathy, bone loss, arteriosclerosis,


L4 ANSWER 1 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
thrombotic disease, indigestion, or memory-learning disorder, or (3) incontinence, lower urinary tract disease, hyperactive bladder, or urinary urgency, or hypotonic bladder accompanied by hyperactive bladder. Thus, amination of 5-(1-acetoxy-2-methylpropyl)-3-bromomethyl-7-(2-fluorobenzyl)-2-(4-methoxyphenyl)-4-oxo-4,7-dihydrothieno[2,3-b]pyridine by N-methylbenzylamine in DMF at room temp. for 2 h gave 3-(N-benzyl-N-methylaminomethyl)-5-(1-acetoxy-2-methylpropyl)-7-(2-fluorobenzyl)-2-(4-methoxyphenyl)-4-oxo-4,7-dihydrothieno[2,3-b]pyridine (II). II.HCl inhibited the binding of [125I]human-RFRP-3-8 peptide having Tyr attached to the N terminus (I.e. Tyr-Val-Pro-Asn-Leu-Pro-Gln-Arg-Phe-NH₂) in CHO cells expressing human OT7022 with IC₅₀ of <1 μM. Pharmaceutical formulations, e.g. tablet contg. II.HCl, were described.

IT 783337-06-4P
RI: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
[preparation of dihydrothieno[2,3-b]pyridine and dihydroimidazo[1,2-a]pyrimidine derivs. as antagonists of RFRP receptor for prevention and treatment of RFRP receptor-related diseases]
RN 783337-06-4 CAPLUS
CN Imidazo[1,2-a]pyrimidine-6-carboxylic acid, 8-[(2,6-difluorophenyl)methyl]-5,8-dihydro-2-(4-methoxyphenyl)-3-[[methyl(phenylmethyl)amino]methyl]-5-oxo-, (9CI) (CA INDEX NAME)




IT 783336-54-9P 783336-55-0P 783336-56-1P
783336-57-2P 783336-58-3P 783336-59-4P
783336-60-7P 783336-61-8P 783336-62-9P
783336-95-8P 783336-96-9P 783337-07-5P
RI: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
[preparation of dihydrothieno[2,3-b]pyridine and dihydroimidazo[1,2-

L4 ANSWER 1 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
a]pyrimidine derivs. as antagonists of RFRP receptor for prevention and treatment of RFRP receptor-related diseases)
RN 783336-54-9 CAPLUS
CN Imidazo[1,2-a]pyrimidine-6-carboxylic acid, 8-[(2,6-difluorophenyl)methyl]-2-[4-(2-furanylmethoxy)phenyl]-5,8-dihydro-3-[[methyl(phenylmethyl)amino]methyl]-5-oxo-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 783336-55-0 CAPLUS
CN Imidazo[1,2-a]pyrimidine-6-carboxylic acid, 8-[(2,6-difluorophenyl)methyl]-5,8-dihydro-2-(4-methoxyphenyl)-3-[[methyl(phenylmethyl)amino]methyl]-5-oxo-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 783336-56-1 CAPLUS
CN Imidazo[1,2-a]pyrimidine-6-carboxamide, 8-[(2,6-difluorophenyl)methyl]-N-[3-(dimethylamino)propyl]-5,8-dihydro-2-(4-methoxyphenyl)-3-[[methyl(phenylmethyl)amino]methyl]-5-oxo-, dihydrochloride (9CI) (CA

L4 ANSWER 1 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
INDEX NAME)

RN 783336-57-2 CAPLUS
CN Imidazo[1,2-a]pyrimidine-6-carboxamide, 8-[(2,6-difluorophenyl)methyl]-5,8-dihydro-N-[3-(1H-imidazol-1-yl)propyl]-2-(4-methoxyphenyl)-3-[[methyl(phenylmethyl)amino]methyl]-5-oxo-, monohydrochloride (9CI) (CA INDEX NAME)



PAGE 1-A


PAGE 2-A

PAGE 1-A

L4 ANSWER 1 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
PAGE 2-A


● HCl

RN 783336-58-3 CAPLUS
CN Thiomorpholine, 4-[[8-[(2,6-difluorophenyl)methyl]-5,8-dihydro-2-(4-methoxyphenyl)-3-[[methyl(phenylmethyl)amino]methyl]-5-oxoimidazo[1,2-a]pyrimidin-6-yl]carbonyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 783336-59-4 CAPLUS
CN Piperazine, 1-[[8-[(2,6-difluorophenyl)methyl]-5,8-dihydro-2-(4-methoxyphenyl)-3-[[methyl(phenylmethyl)amino]methyl]-5-oxoimidazo[1,2-a]pyrimidin-6-yl]carbonyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

L4 ANSWER 1 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl

RN 783336-62-9 CAPLUS
CN Imidazo[1,2-a]pyrimidine-6-carboxylic acid, 2-[4-(cyclopropylmethoxy)phenyl]-8-[(2,6-difluorophenyl)methyl]-5,8-dihydro-3-[[methyl(phenylmethyl)amino]methyl]-5-oxo-, 1,1-dimethylethyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 783336-95-8 CAPLUS
CN Imidazo[1,2-a]pyrimidine-6-carboxylic acid, 2-[4-(cyclopropylmethoxy)phenyl]-8-[(2,6-difluorophenyl)methyl]-5,8-dihydro-3-[[methyl(phenylmethyl)amino]methyl]-5-oxo-, ethyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 783336-60-7 CAPLUS
CN Imidazo[1,2-a]pyrimidine-6-carboxylic acid, 2-[4-(cyclopropylmethoxy)phenyl]-8-[(2,6-difluorophenyl)methyl]-5,8-dihydro-3-[[methyl(phenylmethyl)amino]methyl]-5-oxo-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 783336-61-8 CAPLUS
CN Imidazo[1,2-a]pyrimidine-6-carboxamide, 2-[4-(cyclopropylmethoxy)phenyl]-8-[(2,6-difluorophenyl)methyl]-5,8-dihydro-N-methyl-3-[[methyl(phenylmethyl)amino]methyl]-5-oxo-N-2-pyridinyl-, monohydrochloride (9CI) (CA INDEX NAME)



RN 783336-96-9 CAPLUS
CN Imidazo[1,2-a]pyrimidine-6-carboxamide, 2-[4-(cyclopropylmethoxy)phenyl]-8-[(2,6-difluorophenyl)methyl]-5,8-dihydro-N-methyl-3-[[methyl(phenylmethyl)amino]methyl]-5-oxo-N-2-pyridinyl-, monohydrochloride (9CI) (CA INDEX NAME)



RN 783337-07-5 CAPLUS
CN Imidazo[1,2-a]pyrimidine-6-carboxylic acid, 2-[4-(cyclopropylmethoxy)phenyl]-8-[(2,6-difluorophenyl)methyl]-5,8-dihydro-3-[[methyl(phenylmethyl)amino]methyl]-5-oxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)





IT 229485-44-3 749834-69-3

RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of dihydrothieno[2,3-b]pyridine and dihydroimidazo[1,2-a]pyrimidine derivs. as antagonists of RFRP receptor for prevention and treatment of RFRP receptor-related diseases)

RN 229485-44-3 CAPLUS

CN Imidazo[1,2-a]pyrimidine-6-carboxylic acid, 8-[(2,6-difluorophenyl)methyl]-5,8-dihydro-2-(4-methoxyphenyl)-3-[[methyl(phenylmethyl)amino]methyl]-5-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 749834-69-3 CAPLUS

CN Imidazo[1,2-a]pyrimidine-6-carboxylic acid, 8-[(2,6-difluorophenyl)methyl]-5,8-dihydro-2-(4-methoxyphenyl)-3-[[methyl(phenylmethyl)amino]methyl]-5-oxo-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:491231 CAPLUS

DOCUMENT NUMBER: 139:69279

TITLE:

Preparation of nitrogen-containing heterocyclic compounds as antagonists of gonadotropin-releasing hormone

INVENTOR(S): Furuya, Shuichi; Sasaki, Satoshi; Cho, Nobuo

PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan

SOURCE:

PCT Int. Appl., 64 pp.

CODEN: PIXX02


DOCUMENT TYPE: Patent

LANGUAGE: Japanese


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003051885	A1	20030626	WO 2002-JP13209	20021218
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, US, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
JP 2003183284	A2	20030703	JP 2001-385977	20011219
PRIORITY APPLN. INFO.:				
OTHER SOURCE(S):	MARPAT 139:69279			
GI				



AB The title compds. represented by the following general formula (I) or salts thereof [wherein one of A and D represents nitrogen while the other represents carbon, or both of A and D represent nitrogen; B represents nitrogen or carbon; R represents halogenobenzyl; R1 represents each optionally substituted alkyl, aralkyl, heterocyclyl, aryl, or amino; R2 represents each optionally substituted alkyl or aralkyl; R3 represents H or optionally substituted alkyl; R4 represents a group represented by the following general formula Q (wherein R5 represents halogeno, alkyl, acyl, COOH optionally esterified or amidated, alkoxy, thiol, alkylthio, amino, mono- or dialkylamino, or mono- or diacylamino; and the ring E represents a benzene ring optionally having substituent(s) in addition to R5); and a broken line indicates a single or double bond] are prepared These compds.



L4 ANSWER 2 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

have antagonism to gonadotropin-releasing hormone (GnRH) and are useful for the treatment or prevention of sex hormone-dependent diseases such as sex hormone-dependent cancer, its metastasis to bone, prostatic hypertrophy (prostatomegaly), hysteromyoma, endometriosis, uterine fibroma, true precocious puberty, amenorrhea, premenstrual syndrome, dysmenorrhea, multilocular ovarian syndrome, acne, bald head, Alzheimer's disease, sterility, irritable bowel syndrome, or hormone-independent GnRH-sensitive benign or malignant tumors, for the prevention of recurrence of sex hormone-independent cancer after surgery, or as reprod. regulators, contraceptive agents, or fertility drugs (ovulation inducers). Thus, to a soln. of 100 mg 2-(4-aminophenyl)-3-(N-benzyl-N-methylaminomethyl)-8-(2,6-difluorobenzyl)-5,8-dihydro-6-(4-methoxyphenyl)-5-oxoimidazo[1,2-a]pyrimidine in 5 mL CH₂Cl₂ were added 55 mg 1,1'-carbonyldiimidazole and 0.047 mL Et₃N under ice-cooling, stirred at room temp. for 19 h, followed by adding 141 mg O-methylhydroxylamine hydrochloride and 0.24 mL Et₃N, and the resulting mixt. was stirred at room temp. for 24 h to give, after workup and silica gel chromatog., 3-(N-benzyl-N-methylaminomethyl)-8-(2,6-difluorobenzyl)-5,8-dihydro-2-[[4-[[[(methoxyamino)carbonyl]amino]phenyl]-6-(4-methoxyphenyl)-5-oxoimidazo[1,2-a]pyrimidin-2-yl]phenyl]-5-oxoimidazo[1,2-a]pyrimidine (II). II inhibited the binding of [125I]leuporelin to CHO cell membrane expressing human GnRH receptor with IC₅₀ of 0.2 nM. A tablet, a vial, and a granule formulation contg. II were described.

IT 548761-74-6P 548761-75-7P 548761-76-8P


548761-77-9P, 3-(N-Benzyl-N-methylaminomethyl)-8-(2,6-difluorobenzyl)-5,8-dihydro-2-[[4-[[[(ethylamino)carbonyl]amino]phenyl]-5-oxoimidazo[1,2-a]pyrimidin-2-yl]phenyl]-5-oxoimidazo[1,2-a]pyrimidine (II). II inhibited the binding of [125I]leuporelin to CHO cell membrane expressing human GnRH receptor with IC₅₀ of 0.2 nM. A tablet, a vial, and a granule formulation contg. II were described.

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

of (preparation of nitrogen-containing heterocyclic compds. as antagonists of gonadotropin-releasing hormone for the prevention or treatment of sex hormone-independent diseases)

RN 548761-74-6 CAPLUS


CN 3-Furancarboxamide, N-[4-[8-[(2,6-difluorophenyl)methyl]-5,8-dihydro-6-(4-methoxyphenyl)-3-[[methyl(phenylmethyl)amino]methyl]-5-oxoimidazo[1,2-a]pyrimidin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 548761-75-7 CAPLUS

CN Urea, N-[4-[8-[(2,6-difluorophenyl)methyl]-5,8-dihydro-6-(4-methoxyphenyl)-3-[[methyl(phenylmethyl)amino]methyl]-5-oxoimidazo[1,2-a]pyrimidin-2-yl]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 3-[[methyl(phenylmethyl)amino]methyl]-5-oxoimidazo[1,2-a]pyrimidin-2-yl]phenyl]-N'-ethyl- (9CI) (CA INDEX NAME)




RN 548761-76-8 CAPLUS
 CN Urea, N-[4-[8-[(2,6-difluorophenyl)methyl]-5,8-dihydro-6-(4-methoxyphenyl)-3-[[methyl(phenylmethyl)amino]methyl]-5-oxoimidazo[1,2-a]pyrimidin-2-yl]phenyl]-N'-methoxy- (9CI) (CA INDEX NAME)




RN 548761-77-9 CAPLUS
 CN Urea, N-[4-[8-[(2,6-difluorophenyl)methyl]-5,8-dihydro-3-[[methyl(phenylmethyl)amino]methyl]-5-oxo-6-(1H-pyrrol-1-yl)imidazo[1,2-a]pyrimidin-2-yl]phenyl]-N'-ethyl- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prepn. of nitrogen-contg. heterocyclic compds. as antagonists of gonadotropin-releasing hormone for the prevention or treatment of sex hormone-independent diseases)
 RN 548761-83-7 CAPLUS
 CN Imidazo[1,2-a]pyrimidin-5(8H)-one, 8-[(2,6-difluorophenyl)methyl]-6-(4-methoxyphenyl)-3-[[methyl(phenylmethyl)amino]methyl]-2-(4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 548761-84-8 CAPLUS
 CN Imidazo[1,2-a]pyrimidin-5(8H)-one, 2-(4-aminophenyl)-8-[(2,6-difluorophenyl)methyl]-6-(4-methoxyphenyl)-3-[[methyl(phenylmethyl)amino]methyl]- (9CI) (CA INDEX NAME)




RN 548761-85-9 CAPLUS
 CN Imidazo[1,2-a]pyrimidin-5(8H)-one, 6-amino-8-[(2,6-difluorophenyl)methyl]-3-[[methyl(phenylmethyl)amino]methyl]-2-(4-nitrophenyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




IT 229484-63-3
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of nitrogen-containing heterocyclic compds. as antagonists of gonadotropin-releasing hormone for the prevention or treatment of sex hormone-independent diseases)
 RN 229484-63-3 CAPLUS
 CN Imidazo[1,2-a]pyrimidine-6-carboxylic acid, 8-[(2,6-difluorophenyl)methyl]-5,8-dihydro-3-[[methyl(phenylmethyl)amino]methyl]-2-(4-nitrophenyl)-5-oxo-, ethyl ester (9CI) (CA INDEX NAME)




IT 548761-83-7P 548761-84-8P 548761-85-9P
 548761-86-0P, 2-(4-aminophenyl)-3-[[methyl(phenylmethyl)amino]methyl]-8-(2,6-difluorobenzyl)-5,8-dihydro-5-oxo-6-(1H-pyrrolyl)imidazo[1,2-a]pyrimidine 548761-87-1P 548761-88-2P

L4 ANSWER 2 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)





RN 548761-86-0 CAPLUS
 CN Imidazo[1,2-a]pyrimidin-5(8H)-one, 2-(4-aminophenyl)-8-[(2,6-difluorophenyl)methyl]-3-[[methyl(phenylmethyl)amino]methyl]-6-(1H-pyrrolyl)- (9CI) (CA INDEX NAME)





RN 548761-87-1 CAPLUS
 CN Imidazo[1,2-a]pyrimidine-6-carboxylic acid, 8-[(2,6-difluorophenyl)methyl]-5,8-dihydro-3-[[methyl(phenylmethyl)amino]methyl]-2-(4-nitrophenyl)-5-oxo- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 15 CAPLUS COPYRIGHT 2005 ACS ON STN (Continued)



RN 549761-88-2 CAPLUS
 CN Carbanic acid, [8-[(2,6-difluorophenyl)methyl]-5,8-dihydro-3-[[methyl(phenylmethyl)amino]methyl]-2-(4-nitrophenyl)-5-oximidazo[1,2-a]pyrimidin-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2005 ACS ON STN (Continued)

L4 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2005 ACS ON STN

ACCESSION NUMBER: 2003:238711 CAPLUS
 DOCUMENT NUMBER: 138:395424
 TITLE: Design and Structure-Activity Relationships of 2-Alkyl-3-aninomethyl-6-(3-methoxyphenyl)-7-methyl-8-(2-fluorobenzyl)imidazo[1,2-a]pyrimidin-5-ones as Potent GnRH Receptor Antagonists
 AUTHOR(S): Zhu, Yun-Fei; Guo, Zhiqiang; Gross, Timothy D.; Gao, Yinghong; Connors, Patrick J., Jr.; Struthers, R. Scott; Xie, Qiu; Tucci, Fabio C.; Reinhart, Greg J.; Wu, Dongpei; Saunders, John; Chen, Chen
 CORPORATE SOURCE: Department of Medicinal Chemistry and Department of Exploratory Discovery, Neurocrine Biosciences Inc., San Diego, CA, 92121, USA
 SOURCE: Journal of Medicinal Chemistry (2003), 46(9), 1769-1772
 CODEN: JMCNAR; ISSN: 0022-2623
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 138:395424
 AB SAR studies of 7-phenylpyrrolo[1,2-a]pyrimidin-4-ones and 2-phenylimidazo[1,2-a]pyrimidines as nonpeptide human GnRH receptor antagonists, lead us to believe that the aromatic ring at position-2 of the pyrimidines is no longer crucial for the binding once an aryl group is incorporated at position-6. We report here the use of a 2-alkyl group on the imidazo[1,2-a]pyrimidine core to generate potent GnRH receptor antagonists. This discovery enabled us to obtain smaller but equally potent GnRH receptor antagonists.
 IT 485404-49-7
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (preparation and structure-activity relationships of imidazopyrimidones as GnRH receptor antagonists)
 RN 485404-49-7 CAPLUS
 CN Imidazo[1,2-a]pyrimidin-5(8H)-one, 8-[(2-fluorophenyl)methyl]-6-(3-methoxyphenyl)-2-(4-methoxyphenyl)-7-methyl-3-[[methyl[2-(2-pyridinyl)ethyl]amino]methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2005 ACS ON STN (Continued)

L4 ANSWER 4 OF 15 CAPLUS COPYRIGHT 2005 ACS ON STN

ACCESSION NUMBER: 2002:907162 CAPLUS
 DOCUMENT NUMBER: 137:380043
 TITLE: Treatment of dementia and neurodegenerative diseases with intermediate doses of LHRH antagonists
 INVENTOR(S): Engel, Jurgen; Voegeli, Rainer
 PATENT ASSIGNEE(S): Germany
 SOURCE: U.S. Pat. Appl. Publ., 3 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002177556	A1	20021128	US 2002-133967	20020427
CA 2444876	AA	20021227	CA 2002-2444876	20020427
WO 2002102401	A1	20021227	WO 2002-EP4677	20020427
W: AU, BG, BR, BY, CA, CN, CO, CZ, EE, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LT, LV, MK, MX, NO, NZ, PL, RO, RU, SG, SI, SK, UA, UZ, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
EP 1392349	A1	20040303	EP 2002-735312	20020427
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, TR				
BR 2002009290	A	20040713	BR 2002-9290	20020427
JP 2004529207	T2	20040924	JP 2003-504987	20020427
ZA 2003005326	A	20030730	ZA 2003-5326	20030710
NO 2003004322	A	20030926	NO 2003-4322	20030926
BG 108339	A	20041130	BG 2003-108339	20031110
PRIORITY APPL. INFO.: US 2001-287434P P 20010430 WO 2002-EP4677 W 20020427				
AB The present invention relates to the treatment of dementia and neurodegenerative diseases like Alzheimer's disease with intermediate doses of LHRH antagonists which do not cause a castration. A preferred LHRH antagonist is cetrorelix.				
IT 308143-00-2 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (LHRH antagonist; treatment of dementia and neurodegenerative diseases with intermediate doses of LHRH antagonists)				
RN 308143-00-2 CAPLUS				
CN Imidazo[1,2-a]pyrimidine-6-carboxylic acid, 2-(2,5-dimethyl-3-furanyl)-8-[(2-fluorophenyl)methyl]-5,8-dihydro-3-[[methyl[2-(2-pyridinyl)ethyl]amino]methyl]-5-oxo-, 1-ethylpropyl ester (9CI) (CA INDEX NAME)				

L4 ANSWER 4 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



L4 ANSWER 5 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN


ACCESSION NUMBER: 2002:846214 CAPLUS
 DOCUMENT NUMBER: 138:348294
 TITLE: A novel synthesis of 7-aryl-8-fluoro-pyrrolo[1,2-a]pyrimidin-4-ones as potent, stable GnRH receptor antagonists
 AUTHOR(S): Tucci, Fabio C.; Zhu, Yun-Fei; Guo, Zhiqiang; Gross, Timothy D.; Connors, Patrick J.; Struthers, R. Scott; Reinhart, Greg J.; Wang, Xiaochuan; Saunders, John; Chen, Chen
 CORPORATE SOURCE: Neurocrine Biosciences, Inc., San Diego, CA 92121, USA
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2002), 12(23), 3491-3495
 CODEN: BMCLB; ISSN: 0960-894X
 PUBLISHER: Elsevier Science Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 138:348294
 GI




AB A new class of small mol. GnRH antagonists, the 7-aryl-8-fluoro-pyrrolo[1,2-a]pyrimidin-4-ones, was designed and a novel synthesis for these compds. was developed. The synthesis utilizes a base-catalyzed intramolecular cyclization of a fluoromethyl pyrimidinone to generate the bicyclic core. Amongst the compds. synthesized, we discovered some highly potent GnRH receptor antagonists (e.g., I, $K_i = 9$ nM), which showed enhanced stability towards acidic physiol. conditions compared to the des-fluoro analogs.
 IT 308142-94-1P 308142-95-2P 308142-96-3P
 308142-97-4P 308142-98-5P 308142-99-6P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (synthesis of aryl fluoropyrrolopyrimidones as GnRH receptor antagonists)

L4 ANSWER 5 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

308142-94-1 CAPLUS
 CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-fluoro-1-[(2-fluorophenyl)methyl]-1,4-dihydro-7-[[4-(2-methylpropoxy)phenyl]-6-[[methyl(2-(2-pyridinyl)ethyl)amino]methyl]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)




308142-95-2 CAPLUS
 CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-fluoro-1-[(2-fluorophenyl)methyl]-1,4-dihydro-6-[[methyl(phenylmethyl)amino]methyl]-7-[[4-(2-methylpropoxy)phenyl]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)




308142-96-3 CAPLUS
 CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-fluoro-1-[(2-fluorophenyl)methyl]-6-[[[(2-furanylmethyl)methylamino]methyl]-1,4-dihydro-7-[[4-(2-methylpropoxy)phenyl]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




308142-97-4 CAPLUS
 CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-fluoro-1-[(2-fluorophenyl)methyl]-1,4-dihydro-7-(3-methoxyphenyl)-6-[[methyl(phenylmethyl)amino]methyl]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)




308142-98-5 CAPLUS
 CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-fluoro-1-[(2-fluorophenyl)methyl]-6-[[[(2-furanylmethyl)methylamino]methyl]-1,4-dihydro-7-(3-methoxyphenyl)-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 308142-99-6 CAPLUS
 CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-fluoro-1-[(2-fluorophenyl)methyl]-1,4-dihydro-7-(3-methoxyphenyl)-6-[[methyl(2-pyridinyl)ethyl]amino]methyl]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)




REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN


ACCESSION NUMBER: 2002:543700 CAPLUS
 DOCUMENT NUMBER: 138:122610
 TITLE: A new class of potent nonpeptide luteinizing hormone-releasing hormone (LHRH) antagonists: design and synthesis of 2-phenylimidazo[1,2-a]pyrimidin-5-ones
 AUTHOR(S): Sasaki, Satoshi; Inaeda, Toshihiro; Hayase, Yoji; Shimizu, Yoshiaki; Kasai, Shizuo; Cho, Nobuo; Harada, Masataka; Suzuki, Nobuhiro; Furuya, Shuichi; Fujino, Masahiko
 CORPORATE SOURCE: Pharmaceutical Research Division, Takeda Chemical Industries, Ltd., Tsukuba, Ibaraki, 300-4293, Japan
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2002), 12(16), 2073-2077
 CODEN: BMCLES; ISSN: 0960-894X
 PUBLISHER: Elsevier Science Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 138:122610

AB The design and synthesis of a new class of nonpeptide LH-releasing hormone (LHRH) receptor antagonists, the 2-phenylimidazo[1,2-a]pyrimidin-5-ones, is reported. Among compounds described in this study, we identified a potent antagonist with nanomolar in vitro functional antagonism. The result might suggest that the heterocyclic 5-6-ring system possessing a pendant Ph group attached to the five-membered ring is the important structural feature for a scaffold of small mol. LHRH antagonists.
 IT 229484-79-1P 229484-80-4P 489473-26-9P 489473-27-0P 489473-28-1P 489473-29-2P 489473-30-5P 489473-31-6P 489473-32-7P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
 (acylation of; preparation and biol. evaluation of phenylimidazopyrimidinones as potent nonpeptide LH-releasing hormone antagonists)
 RN 229484-79-1 CAPLUS
 CN Imidazo[1,2-a]pyrimidine-6-carboxylic acid, 8-[(2,6-difluorophenyl)methyl]-5,8-dihydro-2-[[4-[(2-methyl-1-oxopropyl)amino]phenyl]-3-[[methyl(phenylmethyl)amino]methyl]-5-oxo-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 229484-80-4 CAPLUS
 CN Imidazo[1,2-a]pyrimidine-6-carboxylic acid, 8-[(2,6-difluorophenyl)methyl]-2-[[4-[(ethylamino)carbonyl]amino]phenyl]-5,8-dihydro-3-[[methyl(phenylmethyl)amino]methyl]-5-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 489473-26-9 CAPLUS
 CN Imidazo[1,2-a]pyrimidine-6-carboxylic acid, 8-[(2,6-difluorophenyl)methyl]-5,8-dihydro-3-[[methyl(phenylmethyl)amino]methyl]-5-oxo-2-[[4-[(1-oxopropyl)amino]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 6 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 489473-27-0 CAPLUS
 CN Imidazo[1,2-a]pyrimidine-6-carboxylic acid, 2-[[4-[(cyclopropylcarbonyl)amino]phenyl]-8-[(2,6-difluorophenyl)methyl]-5,8-dihydro-3-[[methyl(phenylmethyl)amino]methyl]-5-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 489473-28-1 CAPLUS
 CN Imidazo[1,2-a]pyrimidine-6-carboxylic acid, 8-[(2,6-difluorophenyl)methyl]-5,8-dihydro-3-[[methyl(phenylmethyl)amino]methyl]-5-oxo-2-[[4-[(1-oxopropyl)amino]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 489473-29-2 CAPLUS
CN Imidazo[1,2-a]pyrimidine-6-carboxylic acid, 2-[4-(benzylamino)phenyl]-8-[(2,6-difluorophenyl)methyl]-5,8-dihydro-3-[[methyl(phenylmethyl)amino]methyl]-5-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 489473-30-5 CAPLUS
CN Imidazo[1,2-a]pyrimidine-6-carboxylic acid, 8-[(2,6-difluorophenyl)methyl]-5,8-dihydro-3-[[methyl(phenylmethyl)amino]methyl]-5-oxo-2-[4-[(3-thienylcarbonyl)amino]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




IT 229485-05-6P 229485-06-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (preparation and biol. evaluation of phenylimidazopyrimidinones as potent nonpeptide LH-releasing hormone antagonists)
RN 229485-05-6 CAPLUS
CN Imidazo[1,2-a]pyrimidine-6-carboxylic acid, 8-[(2,6-difluorophenyl)methyl]-5,8-dihydro-2-[4-[[methyl(phenylmethyl)amino]methyl]-3-[[methyl(phenylmethyl)amino]methyl]-5-oxo-, 1-methylethyl ester (9CI) (CA INDEX NAME)




RN 229485-06-7 CAPLUS
CN Imidazo[1,2-a]pyrimidine-6-carboxylic acid, 8-[(2,6-difluorophenyl)methyl]-2-[4-[(ethylamino)carbonyl]amino]phenyl]-5,8-dihydro-3-[[methyl(phenylmethyl)amino]methyl]-5-oxo-, 1-methylethyl ester (9CI) (CA INDEX NAME)




RN 489473-31-6 CAPLUS
CN Imidazo[1,2-a]pyrimidine-6-carboxylic acid, 8-[(2,6-difluorophenyl)methyl]-2-[4-[(3-furanylcarbonyl)amino]phenyl]-5,8-dihydro-3-[[methyl(phenylmethyl)amino]methyl]-5-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 489473-32-7 CAPLUS
CN Imidazo[1,2-a]pyrimidine-6-carboxylic acid, 8-[(2,6-difluorophenyl)methyl]-5,8-dihydro-2-[4-[[methyl(phenylmethyl)amino]methyl]-5-oxo-, ethyl ester (9CI) (CA INDEX NAME)




IT 229484-76-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (reduction of; preparation and biol. evaluation of phenylimidazopyrimidinones as potent nonpeptide LH-releasing hormone antagonists)
RN 229484-76-8 CAPLUS
CN Imidazo[1,2-a]pyrimidine-6-carboxylic acid, 2-(4-aminophenyl)-8-[(2,6-difluorophenyl)methyl]-5,8-dihydro-3-[[methyl(phenylmethyl)amino]methyl]-5-oxo-, ethyl ester (9CI) (CA INDEX NAME)



IT 229484-63-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (reduction of; preparation and biol. evaluation of phenylimidazopyrimidinones as potent nonpeptide LH-releasing hormone antagonists)
RN 229484-63-3 CAPLUS
CN Imidazo[1,2-a]pyrimidine-6-carboxylic acid, 8-[(2,6-difluorophenyl)methyl]-5,8-dihydro-3-[[methyl(phenylmethyl)amino]methyl]-2-(4-nitrophenyl)-5-oxo-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RS FORMAT

L4 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:543699 CAPLUS
DOCUMENT NUMBER: 138:106651
TITLE: Design, synthesis and structure-activity relationships of novel imidazo[1,2-a]pyrimidin-5-ones as potent GnRH receptor antagonists
AUTHOR(S): Gross, Timothy D.; Zhu, Yun-Fei; Saunders, John; Wilcoxon, Keith M.; Gao, Yinghong; Connors, Patrick J.; Guo, Zhiqiang; Struthers, R. Scott; Reinhart, Greg J.; Chen, Chen


CORPORATE SOURCE: Department of Medicinal Chemistry, Neurocrine Biosciences, Inc., San Diego, CA, 92121, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2002), 12(16), 2185-2187

CODEN: BWCLSE, ISSN: 0960-894X
PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 138:106651


AB Structure-activity relationship (SAR) studies of lead GnRH receptor antagonists reported earlier resulted in the discovery of a new compound which showed much higher potency ($K_i=4.6$ nM, compared with previously reported compound, $K_i=230$ nM) in which the 7-position of the imidazo[1,2-a]pyrimidinone core was substituted with a Me group, and the ester at the 6-position was replaced by the 3-methoxyphenyl group.

IT 485404-47-5P 485404-48-6P 485404-49-7P
485404-50-0P 485404-51-1P 485404-52-2P
485404-53-3P 485404-54-4P 485404-55-5P
485404-56-6P 485404-57-7P 485404-59-9P
485404-60-2P 485404-61-3P 485404-62-4P
485404-63-5P 485404-64-6P 485404-65-7P
485404-66-8P 485404-67-9P 485404-68-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and structure-activity relationships of novel imidazopyrimidinones as potent GnRH receptor antagonists)
RN 485404-47-5 CAPLUS
CN Imidazo[1,2-a]pyrimidin-5(8H)-one, 6-bromo-8-[(2-fluorophenyl)methyl]-2-(4-methoxyphenyl)-7-methyl-3-[[methyl[2-(2-pyridinyl)ethyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 485404-48-6 CAPLUS

L4 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN Imidazo[1,2-a]pyrimidin-5(8H)-one, 8-[(2-fluorophenyl)methyl]-6-(2-methoxyphenyl)-2-(4-methoxyphenyl)-7-methyl-3-[[methyl[2-(2-pyridinyl)ethyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 485404-49-7 CAPLUS
CN Imidazo[1,2-a]pyrimidin-5(8H)-one, 8-[(2-fluorophenyl)methyl]-6-(3-methoxyphenyl)-2-(4-methoxyphenyl)-7-methyl-3-[[methyl[2-(2-pyridinyl)ethyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 485404-50-0 CAPLUS
CN Imidazo[1,2-a]pyrimidin-5(8H)-one, 8-[(2-fluorophenyl)methyl]-2,6-bis(4-methoxyphenyl)-7-methyl-3-[[methyl[2-(2-pyridinyl)ethyl]amino]methyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)





RN 485404-51-1 CAPLUS
CN Imidazo[1,2-a]pyrimidin-5(8H)-one, 6-(1,3-benzodioxol-5-yl)-8-[(2-fluorophenyl)methyl]-2-(4-methoxyphenyl)-7-methyl-3-[[methyl[2-(2-pyridinyl)ethyl]amino]methyl]- (9CI) (CA INDEX NAME)





RN 485404-52-2 CAPLUS
CN Imidazo[1,2-a]pyrimidin-5(8H)-one, 6-(3,4-dimethoxyphenyl)-8-[(2-fluorophenyl)methyl]-2-(4-methoxyphenyl)-7-methyl-3-[[methyl[2-(2-pyridinyl)ethyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 485404-53-3 CAPLUS
CN Imidazo[1,2-a]pyrimidin-5(8H)-one, 8-[(2-fluorophenyl)methyl]-2-(4-methoxyphenyl)-7-methyl-3-[[methyl(2-(2-pyridinyl)ethyl)amino]methyl]-6-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 485404-54-4 CAPLUS
CN Imidazo[1,2-a]pyrimidin-5(8H)-one, 6-(3-fluorophenyl)-8-[(2-fluorophenyl)methyl]-2-(4-methoxyphenyl)-7-methyl-3-[[methyl(2-(2-pyridinyl)ethyl)amino]methyl]- (9CI) (CA INDEX NAME)




RN 485404-57-7 CAPLUS
CN Imidazo[1,2-a]pyrimidin-5(8H)-one, 8-[(2-fluorophenyl)methyl]-2-(4-methoxyphenyl)-7-methyl-3-[[methyl(2-(2-pyridinyl)ethyl)amino]methyl]-6-(3-thienyl)- (9CI) (CA INDEX NAME)





RN 485404-59-9 CAPLUS
CN Imidazo[1,2-a]pyrimidin-5(8H)-one, 6-(1,3-benzodioxol-5-yl)-3-[[butylmethylamino]methyl]-8-[(2-fluorophenyl)methyl]-2-(4-methoxyphenyl)-7-methyl- (9CI) (CA INDEX NAME)





RN 485404-55-5 CAPLUS
CN Imidazo[1,2-a]pyrimidin-5(8H)-one, 8-[(2-fluorophenyl)methyl]-2-(4-methoxyphenyl)-7-methyl-3-[[methyl(2-(2-pyridinyl)ethyl)amino]methyl]-6-(3-(trifluoromethyl)phenyl)- (9CI) (CA INDEX NAME)



RN 485404-56-6 CAPLUS
CN Imidazo[1,2-a]pyrimidin-5(8H)-one, 6-(3,5-dichlorophenyl)-8-[(2-fluorophenyl)methyl]-2-(4-methoxyphenyl)-7-methyl-3-[[methyl(2-(2-pyridinyl)ethyl)amino]methyl]- (9CI) (CA INDEX NAME)





RN 485404-60-2 CAPLUS
CN Imidazo[1,2-a]pyrimidin-5(8H)-one, 6-(1,3-benzodioxol-5-yl)-8-[(2-fluorophenyl)methyl]-3-[[[(2-methoxyethyl)methylamino]methyl]-2-(4-methoxyphenyl)-7-methyl- (9CI) (CA INDEX NAME)





RN 485404-61-3 CAPLUS
CN Imidazo[1,2-a]pyrimidin-5(8H)-one, 6-(1,3-benzodioxol-5-yl)-3-[[[(2-diethylamino)ethyl)methylamino]methyl]-8-[(2-fluorophenyl)methyl]-2-(4-methoxyphenyl)-7-methyl- (9CI) (CA INDEX NAME)



L4 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)





L4 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



L4 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



L4 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:543698 CAPLUS

DOCUMENT NUMBER: 138:89758

TITLE: Synthesis and initial structure-activity relationships of a novel series of imidazo[1,2-a]pyrimidin-5-ones as potent GnRH receptor antagonists

AUTHOR(S): Wilcoxon, Keith M.; Zhu, Yun-Fei; Connors, Patrick J.; Saunders, John; Gross, Timothy D.; Gao, Yinghong; Reinhart, Greg J.; Struthers, R. Scott; Chen, Chen
CORPORATE SOURCE: Department of Medicinal Chemistry, Neurocrine Biosciences, Inc., San Diego, CA, 92121, USASOURCE: Bioorganic & Medicinal Chemistry Letters (2002), 12(16), 2179-2183
CODEN: BMLCER; ISSN: 0960-894X

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 138:89758

AB Structure-activity relationships (SAR) studies of 2-arylimidazo[1,2-a]pyrimidin-5-ones resulted in the discovery of a series of potent nonpeptide human GnRH receptor antagonists. Compds. with good potency (e.g., Ki=7.5 nM) were prepared by introduction of a 2-(2-pyridyl)ethyl at the basic nitrogen and a 3-pentyl ester at the 6-position of the bicyclic core.

IT 484691-38-5P 484691-39-6P 484691-40-9P

484691-41-0P 484691-42-1P 484691-43-2P

484691-44-3P 484691-45-4P 484691-46-5P

484691-47-6P 484691-48-7P 484691-49-8P

484691-50-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)



(preparation and initial structure-activity relationships of imidazopyrimidones as potent GnRH receptor antagonists)

RN 484691-38-5 CAPLUS

CN Imidazo[1,2-a]pyrimidine-6-carboxylic acid, 8-[(2-fluorophenyl)methyl]-5,8-dihydro-2-[(4-methoxyphenyl)-3-[(methyl(phenylmethyl)amino)methyl]-5-oxo-, ethyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 8 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN

(Continued)



RN 484691-39-6 CAPLUS

CN Imidazo[1,2-a]pyrimidine-6-carboxylic acid, 8-[(2-fluorophenyl)methyl]-5,8-dihydro-2-[(4-methoxyphenyl)-3-[(methyl(2-(2-pyridinyl)ethyl)amino)methyl]-5-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 484691-40-9 CAPLUS

CN Imidazo[1,2-a]pyrimidine-6-carboxylic acid, 8-[(2-fluorophenyl)methyl]-5,8-dihydro-3-[(methyl(phenylmethyl)amino)methyl]-5-oxo-2-[4-[(1-oxobutyl)amino]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 8 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN

(Continued)




RN 484691-41-0 CAPLUS

CN Imidazo[1,2-a]pyrimidine-6-carboxylic acid, 8-[(2-fluorophenyl)methyl]-5,8-dihydro-3-[(methyl(2-(2-pyridinyl)ethyl)amino)methyl]-5-oxo-2-[4-[(1-oxobutyl)amino]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 484691-42-1 CAPLUS

CN Imidazo[1,2-a]pyrimidine-6-carboxylic acid, 8-[(2-fluorophenyl)methyl]-5,8-dihydro-3-[(methyl(2-(2-pyridinyl)ethyl)amino)methyl]-5-oxo-2-[4-[(1-oxobutyl)amino]phenyl]-, 1-ethylpropyl ester (9CI) (CA INDEX NAME)





L4 ANSWER 8 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN

(Continued)


RN 484691-43-2 CAPLUS

CN Imidazo[1,2-a]pyrimidine-6-carboxylic acid, 8-[(2-fluorophenyl)methyl]-5,8-dihydro-3-[(methyl(2-phenylethyl)amino)methyl]-5-oxo-2-[4-[(1-oxobutyl)amino]phenyl]-, 1-ethylpropyl ester (9CI) (CA INDEX NAME)




RN 484691-44-3 CAPLUS

CN Imidazo[1,2-a]pyrimidine-6-carboxylic acid, 8-[(2-fluorophenyl)methyl]-5,8-dihydro-3-[(methyl(3-pyridinylmethyl)amino)methyl]-5-oxo-2-[4-[(1-oxobutyl)amino]phenyl]-, 1-ethylpropyl ester (9CI) (CA INDEX NAME)




RN 484691-45-4 CAPLUS


CN Imidazo[1,2-a]pyrimidine-6-carboxylic acid, 8-[(2-fluorophenyl)methyl]-3-[[[(2-furanylmethyl)methylamino)methyl]-5,8-dihydro-5-oxo-2-[4-[(1-oxobutyl)amino]phenyl]-, 1-ethylpropyl ester (9CI) (CA INDEX NAME)




RN 484691-46-5 CAPLUS
CN Imidazo[1,2-a]pyrimidine-6-carboxylic acid, 8-[(2-fluorophenyl)methyl]-5,8-dihydro-3-[[[(2-methoxyethyl)methylamino]methyl]-5-oxo-2-[4-[(1-oxobutyl)amino]phenyl]-, 1-ethylpropyl ester (9CI) (CA INDEX NAME)




RN 484691-47-6 CAPLUS
CN Imidazo[1,2-a]pyrimidine-6-carboxylic acid, 3-[[[(cyanomethyl)methylamino]methyl]-8-[(2-fluorophenyl)methyl]-5,8-dihydro-5-oxo-2-[4-[(1-oxobutyl)amino]phenyl]-, 1-ethylpropyl ester (9CI) (CA INDEX NAME)




RN 484691-50-1 CAPLUS
CN Imidazo[1,2-a]pyrimidine-6-carboxylic acid, 8-[(2-fluorophenyl)methyl]-5,8-dihydro-2-[4-[(2-methyl-1-oxopropyl)amino]phenyl]-3-[[methyl(phenylmethyl)amino]methyl]-5-oxo-, 1-ethylpropyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



RN 484691-48-7 CAPLUS
CN Imidazo[1,2-a]pyrimidine-6-carboxylic acid, 3-[(3,4-dihydro-2(1H)-isoquinolinyl)methyl]-8-[(2-fluorophenyl)methyl]-5,8-dihydro-5-oxo-2-[4-[(1-oxobutyl)amino]phenyl]-, 1-ethylpropyl ester (9CI) (CA INDEX NAME)




RN 484691-49-8 CAPLUS
CN Imidazo[1,2-a]pyrimidine-6-carboxylic acid, 8-[(2-fluorophenyl)methyl]-5,8-dihydro-5-oxo-2-[4-[(1-oxobutyl)amino]phenyl]-3-[(1-pyrrolidinyl)methyl]-, 1-ethylpropyl ester (9CI) (CA INDEX NAME)

ACCESSION NUMBER: 2002:345015 CAPLUS
DOCUMENT NUMBER: 136:348358
TITLE: Azo coupling reaction using diazonium salts and couplers having leaving groups, and recording materials containing the couplers
INVENTOR(S): Fujita, Akimori; Matsushita, Tetsunori
PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 21 pp.
CODEN: JKOAKF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2002129048	A2	20020509	JP 2000-329496	20001027
US 2002077252	A1	20020620	US 2001-983856	20011026
US 6645909	B2	20031111		

PRIORITY APPL. INFO.: JP 2000-329496 A 20001027
OTHER SOURCE(S): MARPAT 136:348358
GI




AB Diazonium salts develop colors by azo coupling reaction with couplers I, II, or III [X1-X4 = 5-membered aromatic heterocycle-forming group; Y = (substituted) amino, OH, alkoxy, (substituted) alkyl; L = leaving group which is eliminated as carbonium ion when coupled with diazonium salts; EWG1, EWG2 = electron-withdrawing group; X1Y and EWG1EWG2 may form heterocycle]. Recording materials contain the couplers and diazonium salts which develop colors by coupling reaction with the couplers. The couplers are storage stable and coupled with diazonium salts at high reaction rates, and provide heat-sensitive recording materials giving light-resistant images with good color tone.


IT 418762-29-5
RL: RCT (Reactant); TEM (Technical or engineered material use); RACT (Reactant or reagent); USES (Uses)
(azo coupling of couplers having leaving groups with diazonium salts at high reaction rates for recording materials)

RN 418762-29-5 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-8-carboxylic acid, 2-amino-7-(4-chlorophenyl)-6-[[[dimethylamino]methyl]-1,4-dihydro-4-oxo-3-[[[(phenylamino)sulfonyl]amino]carbonyl]-, 2,6-bis(1,1-dimethylethyl)-4-methylcyclohexyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



ACCESSION NUMBER: 2002:117497 CAPLUS

DOCUMENT NUMBER: 136:167383

TITLE: Preparation of imidazo- and pyrrolo[1,2-a]pyrimidin-4-ones as gonadotropin-releasing hormone receptor antagonists

INVENTOR(S): Zhu, Yun-Fei; Wilcoxon, Keith M.; Struthers, R. Scott; Chen, Chen; Connors, Patrick J., Jr.; Gao, Yinghong; Tucci, Fabio C.

PATENT ASSIGNEE(S): Neurocrine Biosciences, Inc., USA

SOURCE: U.S., 27 pp.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6346534	B1	20020212	US 2000-570239	20000512
US 2002077327	A1	20020620	US 2001-967329	20010928
US 2004142942	A1	20040722	US 2003-690222	20031020
PRIORITY APPLN. INFO.:				
			US 1999-219316P	P 19990923
			US 2000-193335P	P 20000330
			US 2000-287591P	P 20000511
			US 1999-287591P	P 19990514
			US 1999-310878	A2 19990514
			US 1999-219335P	P 19990728
			US 1999-363254	A2 19990728
			US 1999-405286	A2 19990923
			US 2000-570239	A1 20000512
			US 2001-967329	B1 20010928

OTHER SOURCE(S): MARPAT 136:167383


GI




AB The title compds. [I; m = 1-6; R1 = H or (un)substituted (aryl)alkyl, (hetero)aryl, etc.; R2 = H or (un)substituted alkyl; or NR1R2 = (un)substituted heterocycle; R3 and R3b = independently H, OH, alkoxy, thioalkyl, CN, halo, or (un)substituted alkyl, amino, or carbamoyl; or CR3aR3b = (un)substituted carbocyclic ring; R4 = H or (un)substituted (aryl)alkyl, (hetero)aryl, etc.; R5 = H, halo, CN, OH, alkoxy, thioalkyl, (di)alkylamino, or (un)substituted alkyl; R6 = H or (un)substituted alkyl, aryl, heterocyclyl, acyl, carboxy, carbamoyl, etc.; B = N or CR10 when Ar = (un)substituted heteroaryl and R10 = H; or B = CR10 when Ar = (un)substituted aryl, heteroaryl and R10 = halo, CN, NO2, amino, (di)alkylamino, or alkyl] were prepared as gonadotropin-releasing hormone (GnRH) receptor antagonists. For example, 4'-methoxypropiofenone was brominated (73%) and then converted to the amine using NaN3 (100%). Cyclization with malonitrile gave 2-amino-3-cyano-4-(4-methoxyphenyl)-5-methylpyrrole (63%), which was refluxed with di-Et ethoxymethylene malonate to afford the 4H-pyrrolo[1,2-a]pyrimidin-7-one (63%). Addition of 2-fluorobenzyl bromide in the presence of Ag2O in DMF provided II (52%). I are useful for the treatment of a variety of sex-hormone related conditions in both men and women, such as cancer, benign prostatic hypertrophy, myoma of the uterus, endometriosis, polycystic ovarian disease, uterine fibroids, precocious puberty, and prevention of pregnancy (no data).

IT 308142-43-OP 308142-44-1P 308142-45-2P
 308142-46-3P 308142-47-4P 308142-48-5P
 308142-49-6P 308142-50-9P 308142-51-OP
 308142-52-1P 308142-53-2P 308142-54-3P
 308142-55-4P 308142-56-5P 308142-57-6P
 308142-58-7P 308142-59-8P 308142-60-1P
 308142-61-2P 308142-62-3P 308142-63-4P
 308142-64-5P 308142-65-6P 308142-66-7P
 308142-67-8P 308142-68-9P 308142-69-OP
 308142-70-3P 308142-71-4P 308142-72-5P
 308142-73-6P 308142-74-7P 308142-75-8P
 308142-76-9P 308142-77-OP 308142-78-1P


308142-79-2P 308142-80-5P 308142-81-6P
 308142-82-7P 308142-83-8P 308142-84-9P
 308142-85-OP 308142-86-1P 308142-87-2P
 308142-88-3P 308142-89-4P 308142-90-7P
 308142-91-8P 308142-92-9P 308142-93-OP
 308142-94-1P 308142-95-2P 308142-96-3P
 308142-97-4P 308142-98-5P 308142-99-6P
 308143-00-2P 308143-01-3P 308143-02-4P
 308143-03-5P 308143-04-6P 308143-05-7P
 308143-06-8P 308143-07-9P 308143-08-OP
 308144-26-5P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of imidazo- and pyrrolo[1,2-a]pyrimidin-4-ones as gonadotropin-releasing hormone receptor antagonists)
 RN 308142-43-0 CAPLUS
 CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1-[(2-fluorophenyl)methyl]-1,4-dihydro-7-(4-methoxyphenyl)-6-[[methyl(phenylmethyl)amino]methyl]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 308142-44-1 CAPLUS
 CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1-[(2-fluorophenyl)methyl]-1,4-dihydro-7-(4-methoxyphenyl)-6-[[methyl(4-pyridinylmethyl)amino]methyl]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 308142-45-2 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-6-[[[(3,4-dichlorophenyl)methyl]methylamino]methyl]-1-[(2-fluorophenyl)methyl]-1,4-dihydro-7-(4-methoxyphenyl)-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 308142-46-3 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1-[(2-fluorophenyl)methyl]-1,4-dihydro-7-(4-methoxyphenyl)-6-[[methyl-2-propynylamino]methyl]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 308142-49-6 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1-[(2-fluorophenyl)methyl]-1,4-dihydro-7-(4-methoxyphenyl)-6-[[methyl(4-(3-pyridinyl)butyl)amino]methyl]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 308142-50-9 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1-[(2-fluorophenyl)methyl]-1,4-dihydro-7-(4-methoxyphenyl)-6-[[methyl(2-(2-pyridinyl)ethyl)amino]methyl]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 308142-47-4 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-6-[[[(cyclopropylmethyl)propylamino]methyl]-1-[(2-fluorophenyl)methyl]-1,4-dihydro-7-(4-methoxyphenyl)-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 308142-48-5 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-6-[[dimethylamino]methyl]-1-[(2-fluorophenyl)methyl]-1,4-dihydro-7-(4-methoxyphenyl)-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 308142-51-0 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1-[(2-fluorophenyl)methyl]-1,4-dihydro-7-(4-methoxyphenyl)-6-[[methyl(3-methyl-2-pyridinyl)methyl]amino]methyl]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 308142-52-1 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1-[(2-fluorophenyl)methyl]-6-[[[(2-furanylmethyl)methylamino]methyl]-1,4-dihydro-7-(4-methoxyphenyl)-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 308142-53-2 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1-[(2-fluorophenyl)methyl]-1,4-dihydro-6-[[[(2-methoxyethyl)methylamino]methyl]-7-(4-methoxyphenyl)-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 308142-54-3 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1-[(2-fluorophenyl)methyl]-1,4-dihydro-7-(4-methoxyphenyl)-6-[[methyl(2-pyridinylmethyl)amino]methyl]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 308142-57-6 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1-[(2-fluorophenyl)methyl]-1,4-dihydro-7-(4-methoxyphenyl)-6-[[methyl(2-phenylamino)ethyl]amino]methyl]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 308142-58-7 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1-[(2-fluorophenyl)methyl]-1,4-dihydro-6-[[4-hydroxy-4-phenyl-1-piperidinyl]methyl]-7-(4-methoxyphenyl)-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 308142-55-4 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1-[(2-fluorophenyl)methyl]-1,4-dihydro-7-(4-methoxyphenyl)-6-[[methyl(2-propenylamino)methyl]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 308142-56-5 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1-[(2-fluorophenyl)methyl]-1,4-dihydro-6-[[[(3-hydroxy-3-phenylpropyl)methylamino]methyl]-7-(4-methoxyphenyl)-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 308142-59-8 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1-[(2-fluorophenyl)methyl]-1,4-dihydro-7-(4-methoxyphenyl)-6-[[methyl(2-pyridinyl)ethyl]amino]methyl]-4-oxo-, 1-ethylpropyl ester (9CI) (CA INDEX NAME)




RN 308142-60-1 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1-[(2-fluorophenyl)methyl]-1,4-dihydro-7-(4-methoxyphenyl)-6-[[methyl(2-(2-pyridinyl)ethyl)amino]methyl]-4-oxo-, 1-methylethyl ester (9CI) (CA INDEX NAME)




RN 308142-61-2 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1-[(2-fluorophenyl)methyl]-1,4-dihydro-6-[[[(3-hydroxy-3-phenylpropyl)methylamino]methyl]-7-(4-methoxyphenyl)-4-oxo-, 1-methylethyl ester (9CI) (CA INDEX NAME)




RN 308142-62-3 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1-[(2-fluorophenyl)methyl]-1,4-dihydro-7-(4-methoxyphenyl)-6-[[methyl[2-(2-pyridinyl)ethyl]amino]methyl]-4-oxo-, dicyclopropylmethyl ester (9CI) (CA INDEX NAME)




RN 308142-65-6 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1-[(2-fluorophenyl)methyl]-1,4-dihydro-7-(4-methoxyphenyl)-4-oxo-6-[[[(2-pyridinyl)methyl]amino]methyl]-, cyclopentyl ester (9CI) (CA INDEX NAME)




RN 308142-66-7 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1-[(2-fluorophenyl)methyl]-1,4-dihydro-7-(4-methoxyphenyl)-6-[[methyl[2-(2-pyridinyl)ethyl]amino]methyl]-4-oxo-, tetrahydro-3-furanyl ester (9CI) (CA INDEX NAME)




RN 308142-63-4 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1-[(2-fluorophenyl)methyl]-1,4-dihydro-7-(4-methoxyphenyl)-6-[[methyl[2-(2-pyridinyl)ethyl]amino]methyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 308142-64-5 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1-[(2-fluorophenyl)methyl]-1,4-dihydro-7-(4-methoxyphenyl)-6-[[methyl[2-(2-pyridinyl)ethyl]amino]methyl]-4-oxo-, cyclopentyl ester (9CI) (CA INDEX NAME)




RN 308142-67-8 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1-[(2-fluorophenyl)methyl]-1,4-dihydro-7-(4-methoxyphenyl)-6-[[methyl[2-(2-pyridinyl)ethyl]amino]methyl]-4-oxo-, 2-methyl-1-(1-methylethyl)propyl ester (9CI) (CA INDEX NAME)




RN 308142-68-9 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1,4-dihydro-7-(4-methoxyphenyl)-6-[[methyl[2-(2-pyridinyl)ethyl]amino]methyl]-4-oxo-1-(phenylmethyl)-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 10 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 308142-69-0 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1-[(2,6-difluorophenyl)methyl]-1,4-dihydro-7-(4-methoxyphenyl)-6-[[methyl[2-(2-pyridinyl)ethyl]amino]methyl]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 308142-70-3 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1,4-dihydro-7-(4-methoxyphenyl)-6-[[methyl[2-(2-pyridinyl)ethyl]amino]methyl]-4-oxo-1-(3-phenyl-2-propenyl)-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 10 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 308142-71-4 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1-(cyclopropylmethyl)-1,4-dihydro-7-(4-methoxyphenyl)-6-[[methyl[2-(2-pyridinyl)ethyl]amino]methyl]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 308142-72-5 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 1-[(2-chlorophenyl)methyl]-8-cyano-1,4-dihydro-7-(4-methoxyphenyl)-6-[[methyl[2-(2-pyridinyl)ethyl]amino]methyl]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 10 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 308142-73-6 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 1-[[[3,5-bis(trifluoromethyl)phenyl]methyl]-8-cyano-1,4-dihydro-7-(4-methoxyphenyl)-6-[[methyl[2-(2-pyridinyl)ethyl]amino]methyl]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 308142-74-7 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1,4-dihydro-7-(4-methoxyphenyl)-1-[(2-methoxyphenyl)methyl]-6-[[methyl[2-(2-pyridinyl)ethyl]amino]methyl]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 10 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 308142-75-8 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1,4-dihydro-7-(4-methoxyphenyl)-1-[(2-methoxyphenyl)methyl]-6-[[methyl[2-(2-pyridinyl)ethyl]amino]methyl]-4-oxo-, 1-methylethyl ester (9CI) (CA INDEX NAME)




RN 308142-76-9 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1,4-dihydro-7-(4-methoxyphenyl)-1-[(2-methoxyphenyl)methyl]-6-[[methyl[2-(2-pyridinyl)ethyl]amino]methyl]-4-oxo-, 1-ethylpropyl ester (9CI) (CA INDEX NAME)




RN 308142-77-0 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1-[(3,5-difluorophenyl)methyl]-1,4-dihydro-7-(4-methoxyphenyl)-6-[[methyl[2-(2-pyridinyl)ethyl]amino]methyl]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 308142-78-1 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1-[(2-cyanophenyl)methyl]-1,4-dihydro-7-(4-methoxyphenyl)-6-[[methyl[2-(2-pyridinyl)ethyl]amino]methyl]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 308142-81-6 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-7-(4-(1-ethylpropoxy)phenyl)-1-[(2-fluorophenyl)methyl]-1,4-dihydro-6-[[methyl[2-(2-pyridinyl)ethyl]amino]methyl]-4-oxo-, 1-ethylpropyl ester (9CI) (CA INDEX NAME)




RN 308142-82-7 CAPLUS
CN Imidazo[1,2-a]pyrimidin-5(8H)-one, 2-(2,5-dimethyl-3-furanyl)-8-[(2-fluorophenyl)methyl]-6-(3-methoxyphenyl)-7-methyl-3-[[methyl[2-(2-pyridinyl)ethyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 308142-79-2 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1-[(2,4-difluorophenyl)methyl]-1,4-dihydro-7-(4-methoxyphenyl)-6-[[methyl[2-(2-pyridinyl)ethyl]amino]methyl]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 308142-80-5 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1-[(2,3-difluorophenyl)methyl]-1,4-dihydro-7-(4-methoxyphenyl)-6-[[methyl[2-(2-pyridinyl)ethyl]amino]methyl]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 308142-83-8 CAPLUS
CN Imidazo[1,2-a]pyrimidin-5(8H)-one, 2-(2,5-dimethyl-3-furanyl)-8-[(2-fluorophenyl)methyl]-6-(3-methoxyphenyl)-7-methyl-3-[[methyl(phenylmethyl)amino]methyl]- (9CI) (CA INDEX NAME)




RN 308142-84-9 CAPLUS
CN Imidazo[1,2-a]pyrimidin-5(8H)-one, 3-[[[2-(diethylamino)ethyl]methylamino]methyl]-2-(2,5-dimethyl-3-furanyl)-8-[(2-fluorophenyl)methyl]-6-(3-methoxyphenyl)-7-methyl- (9CI) (CA INDEX NAME)




RN 308142-85-0 CAPLUS
CN Imidazo[1,2-a]pyrimidin-5(8H)-one, 2-(2,5-dimethyl-3-furanyl)-8-((2-fluorophenyl)methyl)-3-[[2-methoxyethyl)methylamino)methyl]-6-(3-methoxyphenyl)-7-methyl- (9CI) (CA INDEX NAME)




RN 308142-86-1 CAPLUS
CN Imidazo[1,2-a]pyrimidin-5(8H)-one, 2-(2,5-dimethyl-3-furanyl)-6-(3-ethoxyphenyl)-8-[[2-fluorophenyl)methyl]-3-[[methyl(phenylmethyl)amino)methyl]- (9CI) (CA INDEX NAME)




RN 308142-87-2 CAPLUS
CN Imidazo[1,2-a]pyrimidin-5(8H)-one, 2-(2,5-dimethyl-3-furanyl)-6-(3-ethoxyphenyl)-8-[[2-fluorophenyl)methyl]-3-[[methyl(2-(2-pyridinyl)ethyl)amino)methyl]- (9CI) (CA INDEX NAME)




RN 308142-88-3 CAPLUS
CN Imidazo[1,2-a]pyrimidin-5(8H)-one, 2-(2,5-dimethyl-3-furanyl)-6-(3-fluorophenyl)-8-[[2-fluorophenyl)methyl]-3-[[methyl(phenylmethyl)amino)methyl]- (9CI) (CA INDEX NAME)




RN 308142-89-4 CAPLUS
CN Imidazo[1,2-a]pyrimidin-5(8H)-one, 2-(2,5-dimethyl-3-furanyl)-6-(3-fluorophenyl)-8-[[2-fluorophenyl)methyl]-3-[[methyl(2-(2-pyridinyl)ethyl)amino)methyl]- (9CI) (CA INDEX NAME)



RN 308142-90-7 CAPLUS
CN Imidazo[1,2-a]pyrimidin-5(8H)-one, 2-(2,5-dimethyl-3-furanyl)-8-[[2-fluorophenyl)methyl]-3-[[methyl(phenylmethyl)amino)methyl]-6-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 308142-91-8 CAPLUS
CN Imidazo[1,2-a]pyrimidin-5(8H)-one, 3-[[2-(dimethylamino)ethyl)methylamino)methyl]-2-(2,5-dimethyl-3-furanyl)-8-[[2-fluorophenyl)methyl]-6-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 308142-92-9 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 7-(2,5-dimethyl-3-furanyl)-1-[[2-fluorophenyl)methyl]-1,4-dihydro-6-[[methyl(2-(2-pyridinyl)ethyl)amino)methyl]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 10 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)





RN 308142-93-0 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 6-[(benzoylmethylamino)methyl]-7-(2,5-dimethyl-3-furanyl)-1-[(2-fluorophenyl)methyl]-1,4-dihydro-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 308142-94-1 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-fluoro-1-[(2-fluorophenyl)methyl]-1,4-dihydro-7-[4-(2-methylpropoxy)phenyl]-6-[[methyl[2-(2-pyridinyl)ethyl]amino]methyl]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 10 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)





RN 308142-97-4 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-fluoro-1-[(2-fluorophenyl)methyl]-1,4-dihydro-7-(3-methoxyphenyl)-6-[[methyl(phenylmethyl)amino]methyl]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 308142-98-5 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-fluoro-1-[(2-fluorophenyl)methyl]-6-[[2-(2-furanylmethyl)methylamino]methyl]-1,4-dihydro-7-(3-methoxyphenyl)-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 10 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 308142-95-2 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-fluoro-1-[(2-fluorophenyl)methyl]-1,4-dihydro-6-[[methyl(phenylmethyl)amino]methyl]-7-[4-(2-methylpropoxy)phenyl]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 308142-96-3 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-fluoro-1-[(2-fluorophenyl)methyl]-6-[[2-(2-furanylmethyl)methylamino]methyl]-1,4-dihydro-7-[4-(2-methylpropoxy)phenyl]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 10 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 308142-99-6 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-fluoro-1-[(2-fluorophenyl)methyl]-1,4-dihydro-7-(3-methoxyphenyl)-6-[[methyl[2-(2-pyridinyl)ethyl]amino]methyl]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 308143-00-2 CAPLUS
CN Imidazo[1,2-a]pyrimidine-6-carboxylic acid, 2-(2,5-dimethyl-3-furanyl)-8-[(2-fluorophenyl)methyl]-5,8-dihydro-3-[[methyl[2-(2-pyridinyl)ethyl]amino]methyl]-5-oxo-, 1-ethylpropyl ester (9CI) (CA INDEX NAME)




RN 308143-01-3 CAPLUS
CN Imidazo[1,2-a]pyrimidin-5(8H)-one, 8-[(2-fluorophenyl)methyl]-6-[(3-methoxyphenyl)methyl]-7-methyl-3-[[methyl(2-(2-pyridinyl)ethyl)amino]methyl]-2-(1-methyl-1H-pyrrol-3-yl)- (9CI) (CA INDEX NAME)




RN 308143-02-4 CAPLUS
CN Imidazo[1,2-a]pyrimidin-5(8H)-one, 8-[(2-fluorophenyl)methyl]-6-[(3-methoxyphenyl)methyl]-7-methyl-3-[[methyl(2-(2-pyridinyl)ethyl)amino]methyl]-2-(2-thienyl)- (9CI) (CA INDEX NAME)




RN 308143-05-7 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1-[(2-cyanophenyl)methyl]-1,4-dihydro-7-(4-methoxyphenyl)-6-[[methyl(phenylmethyl)amino]methyl]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 308143-06-8 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1,4-dihydro-7-(4-methoxyphenyl)-1-[(2-methoxyphenyl)methyl]-6-[[methyl(phenylmethyl)amino]methyl]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)





RN 308143-03-5 CAPLUS
CN Imidazo[1,2-a]pyrimidin-5(8H)-one, 8-[(2-fluorophenyl)methyl]-6-[(3-methoxyphenyl)methyl]-7-methyl-3-[[methyl(2-(2-pyridinyl)ethyl)amino]methyl]-2-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 308143-04-6 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 7-(2,5-dimethyl-3-furanyl)-1-[(2-fluorophenyl)methyl]-1,4-dihydro-6-[[methyl(2-(2-pyridinyl)ethyl)amino]methyl]-4-oxo-, 1-ethylpropyl ester (9CI) (CA INDEX NAME)




RN 308143-07-9 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1-[(2,4-difluorophenyl)methyl]-1,4-dihydro-7-(4-methoxyphenyl)-6-[[methyl(phenylmethyl)amino]methyl]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 308143-08-0 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1-[(2-fluorophenyl)methyl]-1,4-dihydro-6-[[methyl(phenylmethyl)amino]methyl]-7-[4-(2-methylpropoxy)phenyl]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)





RN 308144-26-5 CAPLUS
CN Imidazo[1,2-a]pyrimidin-5(8H)-one, 2-((2,5-dimethyl-3-furanyl)-8-((2-fluorophenyl)methyl)-3-((methyl[2-(2-pyridinyl)ethyl]amino)methyl)-6-(3-pyridinyl))- (9CI) (CA INDEX NAME)





IT 308143-12-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of imidazo- and pyrrolo[1,2-a]pyrimidin-4-ones as gonadotropin-releasing hormone receptor antagonists)
RN 308143-12-6 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1-[(2-fluorophenyl)methyl]-1,4-dihydro-7-(4-hydroxyphenyl)-6-[[methyl[2-(2-

L4 ANSWER 11 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:97683 CAPLUS
DOCUMENT NUMBER: 137:78912
TITLE: A Novel Synthesis of 2-Arylpyrrolo[1,2-a]pyrimidin-7-ones and Their Structure-Activity Relationships as Potent GnRH Receptor Antagonists
AUTHOR(S): Zhu, Yun-Fei; Wilcoxon, Keith; Saunders, John; Guo, Zhiqiang; Gao, Yinghong; Connors, Patrick J., Jr.; Gross, Timothy D.; Tucci, Fabio C.; Scott Struthers, R.; Reinhart, Greg J.; Xie, Qiu; Chen, Chen
CORPORATE SOURCE: Neurocrine Biosciences, Inc., San Diego, CA 92121, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2002), 12(3), 403-406
CODEN: BMCLE; ISSN: 0960-894X
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 137:78912
GI





AB In the process of developing GnRH receptor antagonists, a novel base-catalyzed cyclization of compds. I (R1 = MeO, NO2) was discovered, which led to the 2-arylpyrrolo[1,2-a]pyrimidin-7-one core structures (II, same R1). These intermediates were further modified at positions 1, 2, 4 and 6 to afford a series of potent GnRH antagonists with low nanomolar Ki values.
IT 440093-62-9P 440093-63-0P 440093-64-1P
440093-65-2P 440093-66-3P 440093-67-4P
440093-68-5P 440093-69-6P 440093-70-9P
440093-71-0P 440093-72-1P 440093-73-2P
440093-74-3P 440093-75-4P 440093-76-5P
440093-77-6P 440093-78-7P 440093-79-8P
440093-80-1P 440093-81-2P 440093-82-3P
440093-83-4P 440093-84-5P 440093-85-6P
440093-86-7P 440093-87-8P 440093-88-9P
440093-89-0P 440093-90-3P 440093-91-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of 2-arylpyrrolo[1,2-a]pyrimidin-7-ones and their





REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
structure-activity relationships as potent GnRH receptor antagonists)
RN 440093-62-9 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 1-[(2-fluorophenyl)methyl]-1,4-dihydro-7-(4-methoxyphenyl)-6-[[methyl(phenylmethyl)amino)methyl]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 440093-63-0 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 1-[(2-fluorophenyl)methyl]-1,4-dihydro-7-(4-methoxyphenyl)-6-[[methyl[2-(2-pyridinyl)ethyl]amino)methyl]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 440093-64-1 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 1-[(2-fluorophenyl)methyl]-1,4-dihydro-6-[[methyl(phenylmethyl)amino)methyl]-7-(4-nitrophenyl)-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 11 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 440093-65-2 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 7-[(4-aminophenyl)-1-[(2-fluorophenyl)methyl]-1,4-dihydro-6-[[methyl(phenylmethyl)amino]methyl]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 440093-66-3 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 7-[(4-(acetamino)phenyl)-1-[(2-fluorophenyl)methyl]-1,4-dihydro-6-[[methyl(phenylmethyl)amino]methyl]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 11 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)





RN 440093-69-6 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 1-[(2-fluorophenyl)methyl]-1,4-dihydro-6-[[methyl[2-(2-pyridinyl)ethyl]amino]methyl]-4-oxo-7-[(1-oxobutyl)amino]phenyl-, ethyl ester (9CI) (CA INDEX NAME)





RN 440093-70-9 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 1-[(2-fluorophenyl)methyl]-1,4-dihydro-7-(4-methoxyphenyl)-6-[[methyl(phenylmethyl)amino]methyl]-4-oxo-, 1-ethylpropyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 11 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 440093-67-4 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 1-[(2-fluorophenyl)methyl]-1,4-dihydro-7-[(2-methyl-1-oxopropyl)amino]phenyl]-6-[[methyl(phenylmethyl)amino]methyl]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 440093-68-5 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 1-[(2-fluorophenyl)methyl]-1,4-dihydro-7-[(2-methyl-1-oxopropyl)amino]phenyl]-6-[[methyl[2-(2-pyridinyl)ethyl]amino]methyl]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 11 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 440093-71-0 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 1-[(2-fluorophenyl)methyl]-1,4-dihydro-7-(4-methoxyphenyl)-6-[[methyl[2-(2-pyridinyl)ethyl]amino]methyl]-4-oxo-, 1-ethylpropyl ester (9CI) (CA INDEX NAME)




RN 440093-72-1 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 7-(4-aminophenyl)-1-[(2-fluorophenyl)methyl]-1,4-dihydro-6-[[methyl(phenylmethyl)amino]methyl]-4-oxo-, 1-ethylpropyl ester (9CI) (CA INDEX NAME)




RN 440093-73-2 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 7-[4-(acetylamino)phenyl]-1-[(2-fluorophenyl)methyl]-1,4-dihydro-6-[[methyl(phenylmethyl)amino]methyl]-4-oxo-, 1-ethylpropyl ester (9CI) (CA INDEX NAME)




RN 440093-74-3 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 7-[4-(acetylamino)phenyl]-1-[(2-fluorophenyl)methyl]-1,4-dihydro-6-[[methyl[2-(2-pyridinyl)ethyl]amino]methyl]-4-oxo-, 1-ethylpropyl ester (9CI) (CA INDEX NAME)




RN 440093-77-6 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 6-[[dimethylamino]methyl]-1-[(2-fluorophenyl)methyl]-1,4-dihydro-4-oxo-7-[4-[(1-oxobutyl)amino]phenyl]-, 1-ethylpropyl ester (9CI) (CA INDEX NAME)




RN 440093-78-7 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 6-[[[2-(diethylamino)ethyl]methylamino]methyl]-1-[(2-fluorophenyl)methyl]-1,4-dihydro-4-oxo-7-[4-[(1-oxobutyl)amino]phenyl]-, 1-ethylpropyl ester (9CI) (CA INDEX NAME)




RN 440093-75-4 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 1-[(2-fluorophenyl)methyl]-1,4-dihydro-6-[[methyl(phenylmethyl)amino]methyl]-4-oxo-7-[4-[(1-oxobutyl)amino]phenyl]-, 1-ethylpropyl ester (9CI) (CA INDEX NAME)



RN 440093-76-5 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 1-[(2-fluorophenyl)methyl]-1,4-dihydro-6-[[methyl[2-(2-pyridinyl)ethyl]amino]methyl]-4-oxo-7-[4-[(1-oxobutyl)amino]phenyl]-, 1-ethylpropyl ester (9CI) (CA INDEX NAME)





RN 440093-79-8 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 1-[(2-fluorophenyl)methyl]-1,4-dihydro-6-[[methyl[2-(phenylethyl)amino]methyl]-4-oxo-7-[4-[(1-oxobutyl)amino]phenyl]-, 1-ethylpropyl ester (9CI) (CA INDEX NAME)





RN 440093-80-1 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxamide, N-(1-ethylpropyl)-1-[(2-fluorophenyl)methyl]-1,4-dihydro-6-[[methyl[2-(2-pyridinyl)ethyl]amino]methyl]-4-oxo-7-[4-[(1-oxobutyl)amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 11 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 440093-81-2 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxamide, N-cyclopentyl-1-[(2-fluorophenyl)methyl]-1,4-dihydro-6-[[methyl[2-(2-pyridinyl)ethyl]amino]methyl]-4-oxo-7-[4-[(1-oxobutyl)amino]phenyl]- (9CI) (CA INDEX NAME)



RN 440093-82-3 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxamide, N-butyl-1-[(2-fluorophenyl)methyl]-1,4-dihydro-6-[[methyl[2-(2-pyridinyl)ethyl]amino]methyl]-4-oxo-7-[4-[(1-



L4 ANSWER 11 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A





RN 440093-84-5 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxamide, 1-[(2-fluorophenyl)methyl]-N-hexyl-1,4-dihydro-6-[[methyl[2-(2-pyridinyl)ethyl]amino]methyl]-4-oxo-7-[4-[(1-oxobutyl)amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 11 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)





RN 440093-83-4 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxamide, N-cyclohexyl-1-[(2-fluorophenyl)methyl]-1,4-dihydro-6-[[methyl[2-(2-pyridinyl)ethyl]amino]methyl]-4-oxo-7-[4-[(1-oxobutyl)amino]phenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 11 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 440093-85-6 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxamide, 1-[(2-fluorophenyl)methyl]-1,4-dihydro-N-(2-methoxyethyl)-6-[[methyl[2-(2-pyridinyl)ethyl]amino]methyl]-4-oxo-7-[4-[(1-oxobutyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 440093-86-7 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxamide, 1-[(2-fluorophenyl)methyl]-1,4-dihydro-6-[[methyl[2-(2-pyridinyl)ethyl]amino]methyl]-4-oxo-7-[4-[(1-oxobutyl)amino]phenyl]-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 440093-87-8 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxamide, 1-[(2-fluorophenyl)methyl]-1,4-dihydro-6-[[methyl(phenylmethyl)amino]methyl]-4-oxo-7-[4-[(1-oxobutyl)amino]phenyl]-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 440093-88-9 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxamide, N-butyl-1-[(2-fluorophenyl)methyl]-1,4-dihydro-6-[[methyl(phenylmethyl)amino]methyl]-4-oxo-7-[4-[(1-oxobutyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 440093-91-4 CAPLUS
CN Pyrrolo[1,2-a]pyrimidin-4(1H)-one, 3-[4-[(1,1-dimethylethyl)-4,5-dihydro-2-oxazolyl]-1-[(2-fluorophenyl)methyl]-6-[[methyl[2-(2-pyridinyl)ethyl]amino]methyl]-7-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT




RN 440093-89-0 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxamide, N-butyl-6-[[[2-(diethylamino)ethyl]methylamino]methyl]-1-[(2-fluorophenyl)methyl]-1,4-dihydro-4-oxo-7-[4-[(1-oxobutyl)amino]phenyl]- (9CI) (CA INDEX NAME)





RN 440093-90-3 CAPLUS
CN Pyrrolo[1,2-a]pyrimidin-4(1H)-one, 3-[4,5-dihydro-4,4-dimethyl-2-oxazolyl]-1-[(2-fluorophenyl)methyl]-6-[[methyl[2-(2-pyridinyl)ethyl]amino]methyl]-7-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



ACCESSION NUMBER: 2002:97682 CAPLUS
DOCUMENT NUMBER: 137:87821
TITLE: Initial Structure-Activity Relationship Studies of a Novel Series of Pyrrolo[1,2-a]pyrimidin-7-ones as GnRH Receptor Antagonists
AUTHOR(S): Zhu, Yun-Fei; Struthers, R. Scott; Connors, Patrick J., Jr.; Gao, Yinghong; Gross, Timothy D.; Saunders, John; Wilcoxon, Keith; Reinhart, Greg J.; Ling, Nicholas; Chen, Chen
CORPORATE SOURCE: Neurocrine Biosciences, Inc., San Diego, CA 92121, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2002), 12(3), 399-402
CODEN: BMCLES; ISSN: 0960-894X
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 137:87821
AB Initial SAR studies on 1-aminomethyl-2-aryl-3-cyano-pyrrolo[1,2-a]pyrimidin-7-ones-6-carboxylates as human GnRH receptor antagonists were discussed. 2-(2-Methylaminoethyl)pyridine was discovered to be a key feature for generating active compounds. The best compound from the series had 25 nM (K_i) binding affinity to human GnRH receptor.
IT 308142-43-0P 308142-50-9P 308142-68-9P 308142-69-0P 308142-71-4P 308142-72-5P 308142-74-7P 308142-78-1P 308142-79-2P 308142-80-5P 441787-42-4P 441787-44-6P 441787-52-6P 441787-53-7P 441787-54-8P 441787-55-9P 441787-56-0P 441787-57-1P 441787-58-2P 441787-59-3P 441787-60-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(Initial structure-activity relationship studies of a novel series of pyrrolo[1,2-a]pyrimidin-7-ones as GnRH receptor antagonists)
RN 308142-43-0 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1-[(2-fluorophenyl)methyl]-1,4-dihydro-7-(4-methoxyphenyl)-6-[[methyl(phenylmethyl)amino]methyl]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 RN 308142-50-9 CAPLUS
 CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1-[(2-fluorophenyl)methyl]-1,4-dihydro-7-(4-methoxyphenyl)-6-[[methyl(2-(2-pyridinyl)ethyl)amino]methyl]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)





RN 308142-68-9 CAPLUS
 CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1,4-dihydro-7-(4-methoxyphenyl)-6-[[methyl(2-(2-pyridinyl)ethyl)amino]methyl]-4-oxo-1-(phenylmethyl)-, ethyl ester (9CI) (CA INDEX NAME)





RN 308142-69-0 CAPLUS
 CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1-[(2,6-difluorophenyl)methyl]-1,4-dihydro-7-(4-methoxyphenyl)-6-[[methyl(2-(2-pyridinyl)ethyl)amino]methyl]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)





RN 308142-71-4 CAPLUS
 CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1-(cyclopropylmethyl)-1,4-dihydro-7-(4-methoxyphenyl)-6-[[methyl(2-(2-pyridinyl)ethyl)amino]methyl]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)





RN 308142-72-5 CAPLUS
 CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 1-[(2-chlorophenyl)methyl]-8-cyano-1,4-dihydro-7-(4-methoxyphenyl)-6-[[methyl(2-(2-pyridinyl)ethyl)amino]methyl]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)





RN 308142-74-7 CAPLUS
 CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1,4-dihydro-7-(4-methoxyphenyl)-1-[(2-methoxyphenyl)methyl]-6-[[methyl(2-(2-pyridinyl)ethyl)amino]methyl]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)





RN 308142-78-1 CAPLUS
 CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1-[(2-cyanophenyl)methyl]-1,4-dihydro-7-(4-methoxyphenyl)-6-[[methyl(2-(2-pyridinyl)ethyl)amino]methyl]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 308142-79-2 CAPLUS
 CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1-[(2,4-difluorophenyl)methyl]-1,4-dihydro-7-(4-methoxyphenyl)-6-[[methyl(2-(2-pyridinyl)ethyl)amino]methyl]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 308142-80-5 CAPLUS
 CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1-[(2,3-difluorophenyl)methyl]-1,4-dihydro-7-(4-methoxyphenyl)-6-[[methyl(2-(2-pyridinyl)ethyl)amino]methyl]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 441787-42-4 CAPLUS
 CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-6-
 [(dimethylamino)methyl]-1,4-dihydro-7-(4-methoxyphenyl)-4-oxo-1-
 (phenylmethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 441787-44-6 CAPLUS
 CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1,4-dihydro-7-(4-
 methoxyphenyl)-6-[[methyl(phenylmethyl)amino]methyl]-4-oxo-1-
 (phenylmethyl)-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 441787-52-6 CAPLUS
 CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1-[(2,5-
 difluorophenyl)methyl]-1,4-dihydro-7-(4-methoxyphenyl)-6-[[methyl(2-(2-
 pyridinyl)ethyl)amino]methyl]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 441787-53-7 CAPLUS
 CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1,4-dihydro-1-[(2-
 methoxyphenyl)methyl]-7-[4-(2-methylpropoxy)phenyl]-6-[[methyl(2-(2-
 pyridinyl)ethyl)amino]methyl]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 441787-54-8 CAPLUS
 CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1-[(2,6-
 fluorophenyl)methyl]-1,4-dihydro-7-[4-(2-methylpropoxy)phenyl]-6-
 [[methyl(2-(2-pyridinyl)ethyl)amino]methyl]-4-oxo-, ethyl ester (9CI) (CA
 INDEX NAME)




RN 441787-55-9 CAPLUS
 CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1-[(2,5-
 difluorophenyl)methyl]-1,4-dihydro-7-[4-(2-methylpropoxy)phenyl]-6-
 [[methyl(2-(2-pyridinyl)ethyl)amino]methyl]-4-oxo-, ethyl ester (9CI) (CA
 INDEX NAME)

L4 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 441787-56-0 CAPLUS
 CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1-[(2,6-
 difluorophenyl)methyl]-1,4-dihydro-7-[4-(2-methylpropoxy)phenyl]-6-
 [[methyl(2-(2-pyridinyl)ethyl)amino]methyl]-4-oxo-, ethyl ester (9CI) (CA
 INDEX NAME)




RN 441787-57-1 CAPLUS
 CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1-[(2,4-
 difluorophenyl)methyl]-1,4-dihydro-7-[4-(2-methylpropoxy)phenyl]-6-
 [[methyl(2-(2-pyridinyl)ethyl)amino]methyl]-4-oxo-, ethyl ester (9CI) (CA
 INDEX NAME)

L4 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 441787-58-2 CAPLUS
 CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1-[(2,4-difluorophenyl)methyl]-1,4-dihydro-7-[4-(2-methylpropoxy)phenyl]-6-[[methyl[2-(3-pyridinyl)ethyl]amino]methyl]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 441787-59-3 CAPLUS
 CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1-[(2,4-


L4 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

IT 308142-59-8 308142-60-1 308142-62-3
 308142-64-5 308142-66-7 308142-81-6
 441787-61-7 441787-63-9
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (Initial structure-activity relationship studies of a novel series of pyrrolo[1,2-a]pyrimidin-7-ones as GnRH receptor antagonists)
 RN 308142-59-8 CAPLUS
 CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1-[(2-fluorophenyl)methyl]-1,4-dihydro-7-(4-methoxyphenyl)-6-[[methyl[2-(2-pyridinyl)ethyl]amino]methyl]-4-oxo-, 1-ethylpropyl ester (9CI) (CA INDEX NAME)




RN 308142-60-1 CAPLUS
 CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1-[(2-fluorophenyl)methyl]-1,4-dihydro-7-(4-methoxyphenyl)-6-[[methyl[2-(2-pyridinyl)ethyl]amino]methyl]-4-oxo-, 1-methylethyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 difluorophenyl)methyl]-1,4-dihydro-7-[4-(2-methylpropoxy)phenyl]-6-[[methyl[2-(4-pyridinyl)ethyl]amino]methyl]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 441787-60-6 CAPLUS
 CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1-[(2,4-difluorophenyl)methyl]-1,4-dihydro-6-[[methyl[2-phenylethyl]amino]methyl]-7-[4-(2-methylpropoxy)phenyl]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)





L4 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)





RN 308142-62-3 CAPLUS
 CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1-[(2-fluorophenyl)methyl]-1,4-dihydro-7-(4-methoxyphenyl)-6-[[methyl[2-(2-pyridinyl)ethyl]amino]methyl]-4-oxo-, dicyclopentylmethyl ester (9CI) (CA INDEX NAME)





RN 308142-64-5 CAPLUS
 CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1-[(2-fluorophenyl)methyl]-1,4-dihydro-7-(4-methoxyphenyl)-6-[[methyl[2-(2-pyridinyl)ethyl]amino]methyl]-4-oxo-, cyclopentyl ester (9CI) (CA INDEX NAME)





RN 308142-66-7 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1-[(2-fluorophenyl)methyl]-1,4-dihydro-7-(4-methoxyphenyl)-6-[[methyl[2-(2-pyridinyl)ethyl]amino]methyl]-4-oxo-, tetrahydro-3-furanyl ester (9CI) (CA INDEX NAME)





RN 308142-81-6 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-7-[4-(1-ethylpropoxy)phenyl]-1,4-dihydro-6-[[methyl[2-(2-pyridinyl)ethyl]amino]methyl]-4-oxo-, 1-ethylpropyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



RN 441787-61-7 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1-[(2-fluorophenyl)methyl]-1,4-dihydro-7-[4-(2-methylpropoxy)phenyl]-6-[[methyl[2-(2-pyridinyl)ethyl]amino]methyl]-4-oxo-, 1-ethylpropyl ester (9CI) (CA INDEX NAME)




RN 441787-63-9 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-7-[4-(cyclopentyl)phenyl]-1,4-dihydro-6-[[methyl[2-(2-pyridinyl)ethyl]amino]methyl]-4-oxo-, cyclopentyl ester (9CI) (CA INDEX NAME)

ACCESSION NUMBER: 2001:300723 CAPLUS
DOCUMENT NUMBER: 134:311224
TITLE: Preparation of imidazo[1,2-a]pyrimidin-4-one derivatives and related compounds as gonadotropin-releasing hormone receptor antagonists
INVENTOR(S): Zhu, Yun-fei; Gross, Timothy D.; Gao, Yinghong;
CONOR, Patrick J., Jr.; Guo, Zhiqiang; Chen, Chen
PATENT ASSIGNER(S): Neurocrine Biosciences, Inc., USA
SOURCE: PCT Int. Appl., 69 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001029044	A1	20010426	WO 2000-US28677	20001016
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GR, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2386942	AA	20010426	CA 2000-2386942	20001016
EP 1220857	A1	20020710	EP 2000-973591	20001016
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, MC, IE, SI, LT, LV, FI, RO, MK, CY, AL				
US 6537998	B1	20030325	US 2000-688774	20001016
JP 2003512379	T2	20030402	JP 2001-531842	20001016
AU 769855	B2	20040205	AU 2001-12089	20001016
US 2003216411	A1	20031120	US 2003-353806	20030128
PRIORITY APPL. INFO.:			US 1999-418768	A 19991015
			US 1999-304171P	P 19991015
			US 2000-688774	A3 20001016
			WO 2000-US28677	W 20001016


OTHER SOURCE(S): MARPAT 134:311224
GI



AB The title compds. I (A = N, CR4: B = N, CR5: Q = bond, (CR8aR8b)c2(CR10aR10b); m, r, s = 0-6; Z = bond, O, S, SO2, etc.; R1 = H, alkyl, aryl, acylalkyl, etc.; R2 = H, alkyl; R1NR2 = heterocyclic ring; R3a and R3b = H, alkyl, heterocycle, etc.; R6 = H, alkyl, aryl, etc.; R7 = H, halo, cyano, etc.; Ar = aryl, heteroaryl; GnRH receptor antagonists, were prepared E.g., 3-[N-methyl-N-(2-(2-pyridyl)ethyl)aminomethyl]-5-(3-methoxyphenyl)-6-methyl-2-(tert-butyl)-7-(2-fluorophenyl)methylimidazo[1

L4 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 ,2-a]pyrimidin-4-one was prepd. in three steps from 5-bromo-6-methyl-2-(tert-butyl)-7H-imidazo[1,2-a]pyrimidin-4-one (prepn. given).
 IT 335277-87-7P 335277-88-8P 335277-89-9P
 335277-90-2P 335277-91-3P 335277-92-4P
 335277-93-5P 335277-94-6P 335277-95-7P
 RI: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of imidazo[1,2-a]pyrimidin-4-one derivs. and related compds. as gonadotropin-releasing hormone receptor antagonists)


RN 335277-87-7 CAPLUS
 CN Imidazo[1,2-a]pyrimidin-5(8H)-one, 8-[(2-fluorophenyl)methyl]-6-(3-methoxyphenyl)-7-methyl-3-[(methyl[2-(2-pyridinyl)ethyl]amino)methyl]-2-(tetrahydro-3-methyl-2-oxo-3-furanyl)- (9CI) (CA INDEX NAME)




RN 335277-88-8 CAPLUS
 CN Propanenitrile, 3-[[[8-[(2-fluorophenyl)methyl]-5,8-dihydro-6-(3-methoxyphenyl)-7-methyl-5-oxo-2-(tetrahydro-3-methyl-2-oxo-3-furanyl)imidazo[1,2-a]pyrimidin-3-yl]methyl](phenylmethyl)amino]- (9CI) (CA INDEX NAME)

L4 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 335277-91-3 CAPLUS
 CN Imidazo[1,2-a]pyrimidin-5(8H)-one, 8-[(2-fluorophenyl)methyl]-3-[[4-hydroxy-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]methyl]-6-(3-methoxyphenyl)-7-methyl-2-(tetrahydro-3-methyl-2-oxo-3-furanyl)- (9CI) (CA INDEX NAME)




RN 335277-92-4 CAPLUS
 CN Imidazo[1,2-a]pyrimidin-5(8H)-one, 8-[(2-fluorophenyl)methyl]-6-(3-methoxyphenyl)-7-methyl-3-[[4-[2-nitro-4-(trifluoromethyl)phenyl]-1-piperazinyl]methyl]-2-(tetrahydro-3-methyl-2-oxo-3-furanyl)- (9CI) (CA INDEX NAME)




RN 335277-93-5 CAPLUS
 CN Imidazo[1,2-a]pyrimidin-5(8H)-one, 8-[(2-fluorophenyl)methyl]-3-[[2-furanylmethyl]methylaminomethyl]-6-(3-methoxyphenyl)-7-methyl-2-(tetrahydro-3-methyl-2-oxo-3-furanyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 335277-89-9 CAPLUS
 CN Imidazo[1,2-a]pyrimidin-5(8H)-one, 3-[[4-(1,3-benzodioxol-2-ylmethyl)-1-piperazinyl]methyl]-8-[(2-fluorophenyl)methyl]-6-(3-methoxyphenyl)-7-methyl-2-(tetrahydro-3-methyl-2-oxo-3-furanyl)- (9CI) (CA INDEX NAME)





RN 335277-90-2 CAPLUS
 CN Imidazo[1,2-a]pyrimidin-5(8H)-one, 3-[[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]methyl]-8-[(2-fluorophenyl)methyl]-6-(3-methoxyphenyl)-7-methyl-2-(tetrahydro-3-methyl-2-oxo-3-furanyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 335277-94-6 CAPLUS
 CN Imidazo[1,2-a]pyrimidin-5(8H)-one, 3-[[2-(dimethylamino)ethyl]methylamino]methyl]-8-[(2-fluorophenyl)methyl]-6-(3-methoxyphenyl)-7-methyl-2-(tetrahydro-3-methyl-2-oxo-3-furanyl)- (9CI) (CA INDEX NAME)



RN 335277-95-7 CAPLUS
 CN Imidazo[1,2-a]pyrimidin-5(8H)-one, 8-[(2-fluorophenyl)methyl]-6-(3-methoxyphenyl)-7-methyl-3-[[2-(pyridinyl)methyl]amino]methyl]-2-(tetrahydro-3-methyl-2-oxo-3-furanyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 14 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2000:824254 CAPLUS
 DOCUMENT NUMBER: 134:4944
 TITLE: Preparation of imidazo- and pyrrolo[1,2-a]pyrimidin-4-ones as gonadotropin-releasing hormone receptor antagonists
 INVENTOR(S): Zhu, Yun-Fei; Wilcoxon, Keith M.; Struthers, R. Scott; Chen, Chen; Connors, Patrick, Jr.; Gao, Yinghong; Tucci, Fabio C.
 PATENT ASSIGNEE(S): Neurocrine Biosciences, Inc., USA
 SOURCE: PCT Int. Appl., 72 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000069859	A1	20001123	WO 2000-US13108	20000512
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, GU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM				
KW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2372044	AA	20001123	CA 2000-2372044	20000512
EP 1185530	A1	20020313	EP 2000-930676	20000512
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002544278	T2	20021224	JP 2000-618276	20000512
AU 767440	B2	20031113	AU 2000-48457	20000512
NZ 515460	A	20040625	NZ 2000-515460	20000512
PRIORITY APPL. INFO.: US 1999-310878 A 19990514 US 1999-363254 A 19990728 US 1999-405286 A 19990923 WO 2000-US13108 W 20000512				
OTHER SOURCE(S): MARPAT 134:4944 GI				

L4 ANSWER 14 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




AB The title compds. [I; m = 1-6; R1 = H, alkyl, aryl, etc.; R2 = H, alkyl; NR1R2 = (un)substituted heterocyclic; R3a, R3b = H, alkyl, OR, etc.; CR3aR3b = (un)substituted carbocyclic ring; R4 = H, alkyl, aryl, etc.; R5 = H, halo, CN, etc.; R6 = H, alkyl, aryl, etc.; B = N or CR10 when Ar = (un)substituted heteroaryl and R10 = H; or B = CR10 when Ar = (un)substituted aryl, heteroaryl and R10 = halo, CN, NO2, etc.], GnRH receptor antagonists which have utility in the treatment of a variety of sex-hormone related conditions in both men and women, were prepared E.g., a multi-step synthesis of the pyrrolo[1,2-a]pyrimidin-7-one II was given.


IT 308142-43-0P 308142-44-1P 308142-45-2P
 308142-46-3P 308142-47-4P 308142-48-5P
 308142-49-6P 308142-50-9P 308142-51-0P
 308142-52-1P 308142-53-2P 308142-54-3P
 308142-55-4P 308142-56-5P 308142-57-6P
 308142-58-7P 308142-59-8P 308142-60-1P
 308142-61-2P 308142-62-3P 308142-63-4P
 308142-64-5P 308142-65-6P 308142-66-7P
 308142-67-8P 308142-68-9P 308142-69-0P
 308142-70-3P 308142-71-4P 308142-72-5P
 308142-73-6P 308142-74-7P 308142-75-8P
 308142-76-9P 308142-77-0P 308142-78-1P
 308142-79-2P 308142-80-3P 308142-81-4P
 308142-82-7P 308142-83-8P 308142-84-9P
 308142-85-0P 308142-86-1P 308142-87-2P
 308142-88-3P 308142-89-4P 308142-90-7P
 308142-91-8P 308142-92-9P 308142-93-0P
 308142-94-1P 308142-95-2P 308142-96-3P
 308142-97-4P 308142-98-5P 308142-99-6P
 308143-00-2P 308143-01-3P 308143-02-4P
 308143-03-5P 308143-04-6P 308143-05-7P
 308143-06-8P 308143-07-9P 308143-08-0P
 308144-26-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological


L4 ANSWER 14 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of imidazo- and pyrrolo[1,2-a]pyrimidin-4-ones as gonadotropin-releasing hormone receptor antagonists)
 RN 308142-43-0 CAPLUS
 CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1-[(2-fluorophenyl)methyl]-1,4-dihydro-7-(4-methoxyphenyl)-6-[[methyl(phenylmethyl)amino]methyl]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 308142-44-1 CAPLUS
 CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1-[(2-fluorophenyl)methyl]-1,4-dihydro-7-(4-methoxyphenyl)-6-[[methyl(4-pyridinylmethyl)amino]methyl]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 308142-45-2 CAPLUS
 CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-6-[[[(3,4-dichlorophenyl)methyl]methylamino]methyl]-1-[(2-fluorophenyl)methyl]-1,4-dihydro-7-(4-methoxyphenyl)-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 308142-46-3 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1-[(2-fluorophenyl)methyl]-1,4-dihydro-7-(4-methoxyphenyl)-6-[(methyl-2-propynylamino)methyl]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 308142-47-4 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-6-[[[(cyclopropylmethyl)propylamino]methyl]-1-[(2-fluorophenyl)methyl]-1,4-dihydro-7-(4-methoxyphenyl)-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 308142-50-9 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1-[(2-fluorophenyl)methyl]-1,4-dihydro-7-(4-methoxyphenyl)-6-[[methyl(2-(2-pyridinyl)ethyl)amino]methyl]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 308142-51-0 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1-[(2-fluorophenyl)methyl]-1,4-dihydro-7-(4-methoxyphenyl)-6-[[methyl[(3-methyl-2-pyridinyl)methyl]amino]methyl]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 308142-48-5 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-6-[[dimethylamino]methyl]-1-[(2-fluorophenyl)methyl]-1,4-dihydro-7-(4-methoxyphenyl)-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 308142-49-6 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1-[(2-fluorophenyl)methyl]-1,4-dihydro-7-(4-methoxyphenyl)-6-[[methyl(4-(3-pyridinyl)butyl)amino]methyl]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 308142-52-1 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1-[(2-fluorophenyl)methyl]-6-[[[(2-furanylmethyl)methylamino]methyl]-1,4-dihydro-7-(4-methoxyphenyl)-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 308142-53-2 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1-[(2-fluorophenyl)methyl]-1,4-dihydro-6-[[[(2-methoxyethyl)methylamino]methyl]-7-(4-methoxyphenyl)-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 308142-54-3 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1-[(2-fluorophenyl)methyl]-1,4-dihydro-7-(4-methoxyphenyl)-6-[[methyl(2-pyridinylmethyl)amino]methyl]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 308142-55-4 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1-[(2-fluorophenyl)methyl]-1,4-dihydro-7-(4-methoxyphenyl)-6-[[methyl(2-propenylamino)methyl]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 308142-58-7 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1-[(2-fluorophenyl)methyl]-1,4-dihydro-7-(4-methoxyphenyl)-6-[[methyl(2-piperidinyl)methyl]-7-(4-methoxyphenyl)-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 308142-59-8 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1-[(2-fluorophenyl)methyl]-1,4-dihydro-7-(4-methoxyphenyl)-6-[[methyl(2-pyridinyl)ethyl]amino]methyl]-4-oxo-, 1-ethylpropyl ester (9CI) (CA INDEX NAME)




RN 308142-56-5 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1-[(2-fluorophenyl)methyl]-1,4-dihydro-6-[[[(3-hydroxy-3-phenylpropyl)methylamino]methyl]-7-(4-methoxyphenyl)-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 308142-57-6 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1-[(2-fluorophenyl)methyl]-1,4-dihydro-7-(4-methoxyphenyl)-6-[[methyl(2-phenylmethyl)amino]ethyl]amino]methyl]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 308142-60-1 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1-[(2-fluorophenyl)methyl]-1,4-dihydro-7-(4-methoxyphenyl)-6-[[methyl(2-pyridinyl)ethyl]amino]methyl]-4-oxo-, 1-methylethyl ester (9CI) (CA INDEX NAME)




RN 308142-61-2 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1-[(2-fluorophenyl)methyl]-1,4-dihydro-6-[[[(3-hydroxy-3-phenylpropyl)methylamino]methyl]-7-(4-methoxyphenyl)-4-oxo-, 1-methylethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 308142-62-3 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1-[(2-fluorophenyl)methyl]-1,4-dihydro-7-(4-methoxyphenyl)-6-[[methyl[2-(2-pyridinyl)ethyl]amino]methyl]-4-oxo-, dicyclopropylmethyl ester (9CI) (CA INDEX NAME)




RN 308142-63-4 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1-[(2-fluorophenyl)methyl]-1,4-dihydro-7-(4-methoxyphenyl)-6-[[methyl[2-(2-pyridinyl)ethyl]amino]methyl]-4-oxo- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 308142-66-7 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1-[(2-fluorophenyl)methyl]-1,4-dihydro-7-(4-methoxyphenyl)-6-[[methyl[2-(2-pyridinyl)ethyl]amino]methyl]-4-oxo-, tetrahydro-3-furanyl ester (9CI) (CA INDEX NAME)




RN 308142-67-8 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1-[(2-fluorophenyl)methyl]-1,4-dihydro-7-(4-methoxyphenyl)-6-[[methyl[2-(2-pyridinyl)ethyl]amino]methyl]-4-oxo-, 2-methyl-1-(1-methylethyl)propyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 308142-64-5 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1-[(2-fluorophenyl)methyl]-1,4-dihydro-7-(4-methoxyphenyl)-6-[[methyl[2-(2-pyridinyl)ethyl]amino]methyl]-4-oxo-, cyclopentyl ester (9CI) (CA INDEX NAME)




RN 308142-65-6 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1-[(2-fluorophenyl)methyl]-1,4-dihydro-7-(4-methoxyphenyl)-4-oxo-6-[[[2-(2-pyridinyl)methyl]amino]methyl]-, cyclopentyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 308142-68-9 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1,4-dihydro-7-(4-methoxyphenyl)-6-[[methyl[2-(2-pyridinyl)ethyl]amino]methyl]-4-oxo-1-(phenylmethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 308142-69-0 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1-[(2,6-difluorophenyl)methyl]-1,4-dihydro-7-(4-methoxyphenyl)-6-[[methyl[2-(2-pyridinyl)ethyl]amino]methyl]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 308142-70-3 CAPLUS

CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1,4-dihydro-7-(4-methoxyphenyl)-6-[[methyl[2-(2-pyridinyl)ethyl]amino]methyl]-4-oxo-1-(3-phenyl-2-propenyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 308142-71-4 CAPLUS

CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1-(cyclopropylmethyl)-1,4-dihydro-7-(4-methoxyphenyl)-6-[[methyl[2-(2-pyridinyl)ethyl]amino]methyl]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 308142-74-7 CAPLUS

CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1,4-dihydro-7-(4-methoxyphenyl)-1-[(2-methoxyphenyl)methyl]-6-[[methyl[2-(2-pyridinyl)ethyl]amino]methyl]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 308142-75-8 CAPLUS

CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1,4-dihydro-7-(4-methoxyphenyl)-1-[(2-methoxyphenyl)methyl]-6-[[methyl[2-(2-pyridinyl)ethyl]amino]methyl]-4-oxo-, 1-methylethyl ester (9CI) (CA INDEX NAME)




RN 308142-72-5 CAPLUS

CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 1-[(2-chlorophenyl)methyl]-8-cyano-1,4-dihydro-7-(4-methoxyphenyl)-6-[[methyl[2-(2-pyridinyl)ethyl]amino]methyl]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 308142-73-6 CAPLUS

CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 1-[[3,5-bis(trifluoromethyl)phenyl]methyl]-8-cyano-1,4-dihydro-7-(4-methoxyphenyl)-6-[[methyl[2-(2-pyridinyl)ethyl]amino]methyl]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 308142-76-9 CAPLUS

CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1,4-dihydro-7-(4-methoxyphenyl)-1-[(2-methoxyphenyl)methyl]-6-[[methyl[2-(2-pyridinyl)ethyl]amino]methyl]-4-oxo-, 1-ethylpropyl ester (9CI) (CA INDEX NAME)




RN 308142-77-0 CAPLUS

CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1-[(3,5-difluorophenyl)methyl]-1,4-dihydro-7-(4-methoxyphenyl)-6-[[methyl[2-(2-pyridinyl)ethyl]amino]methyl]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 308142-78-1 CAPLUS
 CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1-[(2-cyanophenyl)methyl]-1,4-dihydro-7-(4-methoxyphenyl)-6-[[methyl[2-(2-pyridinyl)ethyl]amino]methyl]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 308142-79-2 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1-[(2,4-difluorophenyl)methyl]-1,4-dihydro-7-(4-methoxyphenyl)-6-[[methyl(2-(2-pyridinyl)ethyl)amino]methyl]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 308142-82-7 CAPLUS
CN Imidazo[1,2-a]pyrimidin-5(8H)-one, 2-(2,5-dimethyl-3-furanyl)-8-[(2-fluorophenyl)methyl]-6-(3-methoxyphenyl)-7-methyl-3-[[methyl[2-(2-pyridinyl)ethyl]amino]methyl]-(9CI) (CA INDEX NAME)




```


RN      308142-83-8  CAPLUS
CN      Imidazo[1,2-a]pyrimidin-5(8H)-one, 2-(2,5-dimethyl-3-furanyl)-8-[(2-
        fluorophenyl)methyl]-6-(3-methoxyphenyl)-7-methyl-3-
        [[methyl(phenyl)methyl]amino]methyl]- (9CI)  (CA INDEX NAME)

```

L4 ANSWER 14 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 308142-80-5 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1-[(2,3-difluorophenyl)methyl]-1,4-dihydro-7-(4-methoxyphenyl)-6-[[methyl(2-(2-methyl-1-ethyl)amino)methyl]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)




```


RN      308142-81-6  CAPIUS
CN      Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-7-[4-(1-ethoxypropyl)phenyl]-1-[(2-fluorophenyl)methyl]-1,4-dihydro-6-[[methyl(2-(2-pyridinyl)ethyl)amino]methyl]-4-oxo-, 1-ethylpropyl ester (9CI)  (CA
INDEX NAME)

```


L4 ANSWER 14 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 308142-84-9 CAPLUS
 CN Imidazo[1,2-a]pyrimidin-5(8H)-one, 3-[[[2-(diethylamino)ethyl]methylamino]methyl]-2-(2,5-dimethyl-3-furanyl)-8-(2,4-difluorophenyl)methyl]-6-(3-methoxyphenyl)-7-methyl- (9CI) (CA INDEX NAME)




RN 308142-85-0 CAPLUS
CN Imidazo[1,2-a]pyrimidin-5(8H)-one, 2-(2,5-dimethyl-3-furanyl)-8-[(2-fluorophenyl)methyl]-3-[[[2-methoxyethyl)methylamino]methyl]-6-(3-methoxyphenyl)-7-methyl- (9CI) (CA INDEX NAME)



L4 ANSWER 14 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 308142-86-1 CAPLUS

CN Imidazo[1,2-a]pyrimidin-5(8H)-one, 2-(2,5-dimethyl-3-furanyl)-6-(3-ethoxyphenyl)-8-[(2-fluorophenyl)methyl]-3-[[methyl(phenylmethyl)amino]methyl]- (9CI) (CA INDEX NAME)




RN 308142-87-2 CAPLUS

CN Imidazo[1,2-a]pyrimidin-5(8H)-one, 2-(2,5-dimethyl-3-furanyl)-6-(3-ethoxyphenyl)-8-[(2-fluorophenyl)methyl]-3-[[methyl[2-(2-pyridinyl)ethyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 308142-88-3 CAPLUS

CN Imidazo[1,2-a]pyrimidin-5(8H)-one, 2-(2,5-dimethyl-3-furanyl)-6-(3-fluorophenyl)-8-[(2-fluorophenyl)methyl]-3-[[methyl(phenylmethyl)amino]methyl]- (9CI) (CA INDEX NAME)



RN 308142-91-8 CAPLUS

CN Imidazo[1,2-a]pyrimidin-5(8H)-one, 3-[[[2-(dimethylamino)ethyl]methylamino]methyl]-2-(2,5-dimethyl-3-furanyl)-8-[(2-fluorophenyl)methyl]-6-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 308142-92-9 CAPLUS

CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 7-(2,5-dimethyl-3-furanyl)-1-[(2-fluorophenyl)methyl]-1,4-dihydro-6-[[methyl[2-(2-pyridinyl)ethyl]amino]methyl]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)




L4 ANSWER 14 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 308142-89-4 CAPLUS


CN Imidazo[1,2-a]pyrimidin-5(8H)-one, 2-(2,5-dimethyl-3-furanyl)-6-(3-fluorophenyl)-8-[(2-fluorophenyl)methyl]-3-[[methyl[2-(2-pyridinyl)ethyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 308142-90-7 CAPLUS


CN Imidazo[1,2-a]pyrimidin-5(8H)-one, 2-(2,5-dimethyl-3-furanyl)-8-[(2-fluorophenyl)methyl]-3-[[methyl(phenylmethyl)amino]methyl]-6-(3-pyridinyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 308142-93-0 CAPLUS

CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 6-[(benzoylmethylamino)methyl]-7-(2,5-dimethyl-3-furanyl)-1-[(2-fluorophenyl)methyl]-1,4-dihydro-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 308142-94-1 CAPLUS


CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-fluoro-1-[(2-fluorophenyl)methyl]-1,4-dihydro-7-(4-(2-methylpropoxy)phenyl)-6-[[methyl[2-(2-pyridinyl)ethyl]amino]methyl]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 308142-95-2 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-fluoro-1-[(2-fluorophenyl)methyl]-1,4-dihydro-6-[[methyl(phenylmethyl)amino]methyl]-7-[4-(2-methylpropoxy)phenyl]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 308142-96-3 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-fluoro-1-[(2-fluorophenyl)methyl]-6-[[methyl(phenylmethyl)amino]methyl]-1,4-dihydro-7-[4-(2-methylpropoxy)phenyl]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 308142-99-6 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-fluoro-1-[(2-fluorophenyl)methyl]-1,4-dihydro-7-(3-methoxyphenyl)-6-[[methyl(2-(2-pyridinyl)ethyl)amino]methyl]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 308143-00-2 CAPLUS
CN Imidazo[1,2-a]pyrimidine-6-carboxylic acid, 2-(2,5-dimethyl-3-furanyl)-8-[(2-fluorophenyl)methyl]-5,8-dihydro-3-[[methyl(2-(2-pyridinyl)ethyl)amino]methyl]-5-oxo-, 1-ethylpropyl ester (9CI) (CA INDEX NAME)




RN 308142-97-4 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-fluoro-1-[(2-fluorophenyl)methyl]-1,4-dihydro-7-(3-methoxyphenyl)-6-[[methyl(phenylmethyl)amino]methyl]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 308142-98-5 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-fluoro-1-[(2-fluorophenyl)methyl]-6-[[methyl(2-furanylmethyl)methylamino]methyl]-1,4-dihydro-7-(3-methoxyphenyl)-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 308143-01-3 CAPLUS
CN Imidazo[1,2-a]pyrimidin-5(8H)-one, 8-[(2-fluorophenyl)methyl]-6-(3-methoxyphenyl)-7-methyl-3-[[methyl(2-(2-pyridinyl)ethyl)amino]methyl]-2-(1-methyl-1H-pyrrol-3-yl)- (9CI) (CA INDEX NAME)




RN 308143-02-4 CAPLUS
CN Imidazo[1,2-a]pyrimidin-5(8H)-one, 8-[(2-fluorophenyl)methyl]-6-(3-methoxyphenyl)-7-methyl-3-[[methyl(2-(2-pyridinyl)ethyl)amino]methyl]-2-(2-thienyl)- (9CI) (CA INDEX NAME)




RN 308143-03-5 CAPLUS
CN Imidazo[1,2-a]pyrimidin-5(8H)-one, 8-[(2-fluorophenyl)methyl]-6-[(3-methoxyphenyl)methyl]-7-methyl-3-[[methyl[2-(2-pyridinyl)ethyl]amino]methyl]-2-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 308143-04-6 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 7-(2,5-dimethyl-3-furanyl)-1-[(2-fluorophenyl)methyl]-1,4-dihydro-6-[[methyl[2-(2-pyridinyl)ethyl]amino]methyl]-4-oxo-, 1-ethylpropyl ester (9CI) (CA INDEX NAME)




RN 308143-07-9 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1-[(2,4-difluorophenyl)methyl]-1,4-dihydro-7-(4-methoxyphenyl)-6-[[methyl(phenylmethyl)amino]methyl]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 308143-08-0 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1-[(2-fluorophenyl)methyl]-1,4-dihydro-6-[[methyl(phenylmethyl)amino]methyl]-7-[[4-(2-methylpropoxy)phenyl]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 308143-05-7 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1-[(2-cyanophenyl)methyl]-1,4-dihydro-7-(4-methoxyphenyl)-6-[[methyl(phenylmethyl)amino]methyl]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 308143-06-8 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1,4-dihydro-7-(4-methoxyphenyl)-1-[(2-methoxyphenyl)methyl]-6-[[methyl(phenylmethyl)amino]methyl]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 308144-26-5 CAPLUS
CN Imidazo[1,2-a]pyrimidin-5(8H)-one, 2-(2,5-dimethyl-3-furanyl)-8-[(2-fluorophenyl)methyl]-3-[[methyl[2-(2-pyridinyl)ethyl]amino]methyl]-6-(3-pyridinyl)- (9CI) (CA INDEX NAME)



IT 308143-12-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of imidazo- and pyrrolo[1,2-a]pyrimidin-4-ones as gonadotropin-releasing hormone receptor antagonists)
RN 308143-12-6 CAPLUS
CN Pyrrolo[1,2-a]pyrimidine-3-carboxylic acid, 8-cyano-1-[(2-fluorophenyl)methyl]-1,4-dihydro-7-(4-hydroxyphenyl)-6-[[methyl[2-(2-pyridinyl)ethyl]amino]methyl]-4-oxo- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 1999:460419 CAPLUS
 DOCUMENT NUMBER: 131:87922
 TITLE: Nitrogen-containing heterocyclic compounds, including imidazopyrimidines, and their production and use as GnRH antagonists
 INVENTOR(S): Furuya, Shuichi; Imaeda, Toshihiro; Sasaki, Satoshi
 PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
 SOURCE: PCT Int. Appl., 152 pp.
 CODEN: PIXX02
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9933831	A1	19990708	WO 1998-JP5841	19981224
W:	AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LR, LT, LV, MD, ME, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2300479	AA	19990708	CA 1998-2300479	19981224
AU 9916871	A1	19990719	AU 1999-16871	19981224
EP 1042325	A1	20001011	EP 1998-961503	19981224
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
JP 11315079	A2	19991116	JP 1998-368832	19981225
US 6194419	B1	20010227	US 1999-147616	19990202
US 6413972	B1	20020702	US 2000-711139	20001114
US 2002103210	A1	20020801	US 2002-42229	20020111

PRIORITY APPLN. INFO.:

OTHER SOURCE(S): MARPAT 131:87922
 GI




AB Title compds. I (wherein one of A and D is N and the other is C, or both are N; B is N or C; m is 0-3; R1, R2 and R3 are each (i) H or (ii) a group bound via C, N, O or S; R4 is a group bound via C; R5 is H or a group bound via C or O; R6 is H or a group bound via C; R7 is a homo- or heterocyclic group which may be substituted) and salts possess excellent gonadotropin-releasing hormone (GnRH) antagonizing activity, and are useful as prophylactic or therapeutic agents for sex hormone-dependent diseases, including cancer. Thus, title compound II is obtained in 3 steps, by cyclocondensation of 2-amino-4-hydroxypyrimidine-5-carboxylic acid Et ester with 2-bromopropiophenone, followed by reduction with Zn and AcOH, and N-alkylation with 2,6-difluorobenzyl chloride. In a test for inhibition of binding of [125I]-leuporelin at human GnRH receptors expressed in CHO cells, an exemplary compound I showed an IC50 of 0.5 nM.

IT 229484-63-3P 229484-64-4P 229484-65-5P
 229484-66-6P 229484-67-7P 229484-68-8P
 229484-69-9P 229484-70-2P 229484-71-3P
 229484-72-4P 229484-73-5P 229484-74-6P
 229484-76-8P 229484-77-9P 229484-78-0P
 229484-86-0P 229484-91-7P 229484-92-8P
 229485-04-3P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of imidazopyrimidines as gonadotropin-releasing hormone antagonists useful for prevention and treatment of sex hormone dependent diseases and cancer)

RN 229484-63-3 CAPLUS
 CN Imidazo[1,2-a]pyrimidine-6-carboxylic acid, 8-[(2,6-difluorophenyl)methyl]-5,8-dihydro-3-[(methyl(phenylmethyl)amino)methyl]-2-(4-nitrophenyl)-5-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 229484-64-4 CAPLUS
 CN Imidazo[1,2-a]pyrimidin-5(8H)-one, 2-[4-(cyclopropylmethoxy)phenyl]-8-[(2,6-difluorophenyl)methyl]-7-methyl-3-[(methyl(phenylmethyl)amino)methyl]-6-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)





● HCl

RN 229484-65-5 CAPLUS
 CN Propanamide, N-[4-[8-[(2,6-difluorophenyl)methyl]-5,8-dihydro-7-methyl-3-[(methyl(phenylmethyl)amino)methyl]-5-oxo-6-(phenylmethyl)imidazo[1,2-a]pyrimidin-2-yl]phenyl]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)





● HCl


RN 229484-66-6 CAPLUS
 CN Imidazo[1,2-a]pyrimidine-6-carboxylic acid, 3-[[[2-(diethylamino)ethyl]methylamino]methyl]-8-[(2,6-difluorophenyl)methyl]-5,8-dihydro-2-(4-nitrophenyl)-5-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 229484-67-7 CAPLUS
CN Carbamic acid, acetyl[4-[8-[(2,6-difluorophenyl)methyl]-5,8-dihydro-3-[[methyl(phenylmethyl)amino]methyl]-5-oxo-6-phenylimidazo[1,2-a]pyrimidin-2-yl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 229484-68-8 CAPLUS
CN Carbamic acid, acetyl[4-[8-[(2,6-difluorophenyl)methyl]-5,8-dihydro-7-methyl-3-[[methyl(phenylmethyl)amino]methyl]-5-oxo-6-(phenylmethyl)imidazo[1,2-a]pyrimidin-2-yl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)





● HCl

RN 229484-71-3 CAPLUS
CN Imidazo[1,2-a]pyrimidin-5(8H)-one, 2-[4-(cyclopropylmethoxy)phenyl]-8-[(2,6-difluorophenyl)methyl]-6-(4-methoxyphenyl)-3-[[methyl(phenylmethyl)amino]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl



RN 229484-72-4 CAPLUS
CN Imidazo[1,2-a]pyrimidin-5(8H)-one, 8-[(2,6-difluorophenyl)methyl]-6-(3-methyl-1-oxobutyl)-3-[[methyl(phenylmethyl)amino]methyl]-2-(4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 229484-69-9 CAPLUS
CN Imidazo[1,2-a]pyrimidin-5(8H)-one, 2-[4-(cyclopropylmethoxy)phenyl]-8-[(2,6-difluorophenyl)methyl]-3-[[methyl(phenylmethyl)amino]methyl]-6-phenyl- (9CI) (CA INDEX NAME)




RN 229484-70-2 CAPLUS
CN Imidazo[1,2-a]pyrimidin-5(8H)-one, 6-(4-chlorophenyl)-2-[4-(cyclopropylmethoxy)phenyl]-8-[(2,6-difluorophenyl)methyl]-3-[[methyl(phenylmethyl)amino]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)





RN 229484-73-5 CAPLUS
CN Imidazo[1,2-a]pyrimidine-6-carboxylic acid, 8-[(2,6-difluorophenyl)methyl]-5,8-dihydro-2-(4-methoxyphenyl)-3-[[methyl(phenylmethyl)amino]methyl]-5-oxo-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)





● HCl





RN 229484-74-6 CAPLUS
CN Imidazo[1,2-a]pyrimidine-6-carboxylic acid, 2-[4-(acetyloxy)phenyl]-8-[(2,6-difluorophenyl)methyl]-5,8-dihydro-3-[[methyl(phenylmethyl)amino]methyl]-5-oxo-, ethyl ester (9CI) (CA INDEX NAME)





RN 229484-76-8 CAPLUS
CN Imidazo[1,2-a]pyrimidine-6-carboxylic acid, 2-(4-aminophenyl)-8-[(2,6-difluorophenyl)methyl]-5,8-dihydro-3-[[methyl(phenylmethyl)amino]methyl]-5-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 229484-77-9 CAPLUS
CN Imidazo[1,2-a]pyrimidine-6-carboxylic acid, 2-(4-aminophenyl)-3-[[[2-(diethylamino)ethyl]methylamino]methyl]-8-[(2,6-difluorophenyl)methyl]-5,8-dihydro-5-oxo-, ethyl ester (9CI) (CA INDEX NAME)





RN 229484-78-0 CAPLUS
CN Imidazo[1,2-a]pyrimidin-5(8H)-one, 2-(4-aminophenyl)-8-[(2,6-difluorophenyl)methyl]-6-(3-methyl-1-oxobutyl)-3-[[methyl(phenylmethyl)amino]methyl]- (9CI) (CA INDEX NAME)





RN 229484-86-0 CAPLUS
CN Imidazo[1,2-a]pyrimidine-6-carboxamide, 8-[(2,6-difluorophenyl)methyl]-2-[[4-[(3-furanylcarbonyl)amino]phenyl]-5,8-dihydro-N-methoxy-N-methyl-3-[[methyl(phenylmethyl)amino]methyl]-5-oxo- (9CI) (CA INDEX NAME)





RN 229484-91-7 CAPLUS
CN Carbamic acid, [4-[8-[(2,6-difluorophenyl)methyl]-5,8-dihydro-7-methyl-3-[[methyl(phenylmethyl)amino]methyl]-5-oxo-6-(phenylmethyl)imidazo[1,2-a]pyrimidin-2-yl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 229484-92-8 CAPLUS
CN Carbamic acid, [4-[8-[(2,6-difluorophenyl)methyl]-5,8-dihydro-3-[[methyl(phenylmethyl)amino]methyl]-5-oxo-6-phenylimidazo[1,2-a]pyrimidin-2-yl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 229485-04-5 CAPLUS
CN Imidazo[1,2-a]pyrimidine-6-carboxylic acid, 2-(4-aminophenyl)-8-[(2,6-difluorophenyl)methyl]-5,8-dihydro-3-[[methyl(phenylmethyl)amino]methyl]-5-oxo-, 1-methylethyl ester (9CI) (CA INDEX NAME)




IT 229484-79-1P 229484-80-4P 229484-81-5P
229484-82-6P 229484-83-7P 229484-84-8P
229484-85-9P 229484-87-1P 229484-88-2P
229484-93-9P 229484-94-0P 229485-02-3P
229485-03-4P 229485-05-6P 229485-06-7P
229485-07-8P 229485-08-9P 229485-09-0P
229485-10-3P 229485-11-4P 229485-12-5P
229485-13-6P 229485-14-7P 229485-15-8P
229485-16-9P 229485-17-0P 229485-18-1P
229485-19-2P 229485-20-5P 229485-21-6P
229485-22-7P 229485-23-8P 229485-24-9P
229485-25-0P 229485-26-1P 229485-28-3P
229485-30-7P 229485-32-9P 229485-34-1P

L4 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

229485-35-2P 229485-36-3P 229485-37-4P
 229485-38-5P 229485-39-6P 229485-40-9P
 229485-41-0P 229485-42-1P 229485-43-2P
 229485-44-3P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of imidazopyrimidines as gonadotropin-releasing hormone antagonists useful for prevention and treatment of sex hormone dependent diseases and cancer)

RN 229484-79-1 CAPLUS
 CN Imidazo[1,2-a]pyrimidine-6-carboxylic acid, 8-[(2,6-difluorophenyl)methyl]-5,8-dihydro-2-[4-[(2-methyl-1-oxopropyl)amino]phenyl]-3-[[methyl(phenylmethyl)amino]methyl]-5-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 229484-80-4 CAPLUS
 CN Imidazo[1,2-a]pyrimidine-6-carboxylic acid, 8-[(2,6-difluorophenyl)methyl]-2-[4-[[[(ethylamino)carbonyl]amino]phenyl]-5,8-dihydro-3-[[methyl(phenylmethyl)amino]methyl]-5-oxo-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 229484-83-7 CAPLUS
 CN 3-Furancarboxamide, N-[4-[8-[(2,6-difluorophenyl)methyl]-5,8-dihydro-3-[[methyl(phenylmethyl)amino]methyl]-5-oxo-6-phenylimidazo[1,2-a]pyrimidin-2-yl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




RN 229484-84-8 CAPLUS
 CN 3-Furancarboxamide, N-[4-[8-[(2,6-difluorophenyl)methyl]-5,8-dihydro-7-methyl-3-[[methyl(phenylmethyl)amino]methyl]-5-oxo-6-(phenylmethyl)imidazo[1,2-a]pyrimidin-2-yl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 229484-81-5 CAPLUS
 CN Imidazo[1,2-a]pyrimidine-6-carboxylic acid, 3-[[[2-(diethylamino)ethyl]methylamino]methyl]-8-[(2,6-difluorophenyl)methyl]-5,8-dihydro-2-[4-[(2-methyl-1-oxopropyl)amino]phenyl]-5-oxo-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)




RN 229484-82-6 CAPLUS
 CN Imidazo[1,2-a]pyrimidine-6-carboxylic acid, 3-[[[2-(diethylamino)ethyl]methylamino]methyl]-8-[(2,6-difluorophenyl)methyl]-2-[4-[[[(ethylamino)carbonyl]amino]phenyl]-5,8-dihydro-5-oxo-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)


L4 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 229484-85-9 CAPLUS
 CN Urea, N-[4-[8-[(2,6-difluorophenyl)methyl]-5,8-dihydro-7-methyl-3-[[methyl(phenylmethyl)amino]methyl]-5-oxo-6-(phenylmethyl)imidazo[1,2-a]pyrimidin-2-yl]phenyl]-N'-methoxy- (9CI) (CA INDEX NAME)



RN 229484-87-1 CAPLUS
 CN Imidazo[1,2-a]pyrimidine-6-carboxamide, 2-[4-[(cyclopropylcarbonyl)amino]phenyl]-8-[(2,6-difluorophenyl)methyl]-5,8-dihydro-N-methoxy-N-methyl-3-[[methyl(phenylmethyl)amino]methyl]-5-oxo- (9CI) (CA INDEX NAME)




RN 229484-88-2 CAPLUS
CN 3-Furancarboxamide, N-[4-[(2,6-difluorophenyl)methyl]-5,8-dihydro-6-(3-methyl-1-oxobutyl)-3-[[methyl(phenylmethyl)amino]methyl]-5-oxoimidazo[1,2-a]pyrimidin-2-yl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)





● HCl



RN 229484-93-9 CAPLUS
CN Imidazo[1,2-a]pyrimidin-5(8H)-one, 2-(4-aminophenyl)-8-[(2,6-difluorophenyl)methyl]-7-methyl-3-[[methyl(phenylmethyl)amino]methyl]-6-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 229484-94-0 CAPLUS
CN Imidazo[1,2-a]pyrimidin-5(8H)-one, 2-(4-aminophenyl)-8-[(2,6-difluorophenyl)methyl]-3-[[methyl(phenylmethyl)amino]methyl]-6-phenyl- (9CI) (CA INDEX NAME)





RN 229485-02-3 CAPLUS
CN Imidazo[1,2-a]pyrimidine-6-carboxamide, 2-(4-aminophenyl)-8-[(2,6-difluorophenyl)methyl]-5,8-dihydro-N-methoxy-N-methyl-3-[[methyl(phenylmethyl)amino]methyl]-5-oxo- (9CI) (CA INDEX NAME)





RN 229485-03-4 CAPLUS
CN 3-Furancarboxamide, N-[4-[(2,6-difluorophenyl)methyl]-5,8-dihydro-3-[[methyl(phenylmethyl)amino]methyl]-5-oxoimidazo[1,2-a]pyrimidin-2-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 229485-05-6 CAPLUS
CN Imidazo[1,2-a]pyrimidine-6-carboxylic acid, 8-[(2,6-difluorophenyl)methyl]-5,8-dihydro-2-[4-[[[(methoxyamino)carbonyl]amino]phenyl]-3-[[methyl(phenylmethyl)amino]methyl]-5-oxo-, 1-methylethyl ester (9CI) (CA INDEX NAME)




RN 229485-06-7 CAPLUS
CN Imidazo[1,2-a]pyrimidine-6-carboxylic acid, 8-[(2,6-difluorophenyl)methyl]-2-[4-[[[(ethoxycarbonyl)amino]phenyl]-3-[[methyl(phenylmethyl)amino]methyl]-5-oxo-, 1-methylethyl ester (9CI) (CA INDEX NAME)



RN 229485-07-8 CAPLUS
CN Imidazo[1,2-a]pyrimidine-6-carboxylic acid, 8-[(2,6-difluorophenyl)methyl]-5,8-dihydro-2-[4-[(3-hydroxy-1-oxopropyl)amino]phenyl]-3-[[methyl(phenylmethyl)amino]methyl]-5-oxo-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


PAGE 1-A



● HCl

RN 229485-08-9 CAPLUS

CN Imidazo[1,2-a]pyrimidine-6-carboxylic acid, 8-[(2,6-difluorophenyl)methyl]-5,8-dihydro-2-[4-[(methoxycarbonyl)amino]phenyl]-3-[[methyl(phenylmethyl)amino]methyl]-5-oxo-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

L4 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 229485-09-0 CAPLUS

CN Imidazo[1,2-a]pyrimidine-6-carboxylic acid, 8-[(2,6-difluorophenyl)methyl]-2-[4-[[[(3,5-dimethyl-4-isoxazolyl)carbonyl]amino]phenyl]-5,8-dihydro-3-[[methyl(phenylmethyl)amino]methyl]-5-oxo-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 229485-10-3 CAPLUS

CN Imidazo[1,2-a]pyrimidine-6-carboxylic acid, 8-[(2,6-difluorophenyl)methyl]-5,8-dihydro-2-[4-[(5-isoxazolylcarbonyl)amino]phenyl]-3-[[methyl(phenylmethyl)amino]methyl]-5-oxo-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)


L4 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl


RN 229485-11-4 CAPLUS

CN Imidazo[1,2-a]pyrimidine-6-carboxylic acid, 8-[(2,6-difluorophenyl)methyl]-5,8-dihydro-3-[[methyl(phenylmethyl)amino]methyl]-2-[4-[[[(5-nitro-3-thienyl)carbonyl]amino]phenyl]-5-oxo-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


L4 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl

RN 229485-13-6 CAPLUS

CN Imidazo[1,2-a]pyrimidine-6-carboxylic acid, 8-[(2,6-difluorophenyl)methyl]-5,8-dihydro-2-[4-[[[(4-methoxy-3-thienyl)carbonyl]amino]phenyl]-3-[[methyl(phenylmethyl)amino]methyl]-5-oxo-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 229485-14-7 CAPLUS

CN Imidazo[1,2-a]pyrimidine-6-carboxylic acid, 8-[(2,6-difluorophenyl)methyl]-2-[4-[[[(1,5-dimethyl-1H-pyrazol-3-yl)carbonyl]amino]phenyl]-5,8-dihydro-3-[[methyl(phenylmethyl)amino]methyl]-5-oxo-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)


RN 229485-12-5 CAPLUS

CN Imidazo[1,2-a]pyrimidine-6-carboxylic acid, 8-[(2,6-difluorophenyl)methyl]-2-[4-[[[(2,4-dimethyl-5-thiazolyl)carbonyl]amino]phenyl]-5,8-dihydro-3-[[methyl(phenylmethyl)amino]methyl]-5-oxo-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 229485-15-8 CAPLUS
 CN Imidazo[1,2-a]pyrimidine-6-carboxylic acid, 8-[(2,6-difluorophenyl)methyl]-2-[4-[(3-furanylcarbonyl)amino]phenyl]-5,8-dihydro-3-[[methyl(phenylmethyl)amino]methyl]-5-oxo-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 229485-16-9 CAPLUS
 CN Imidazo[1,2-a]pyrimidine-6-carboxylic acid, 8-[(2,6-difluorophenyl)methyl]-5,8-dihydro-2-[4-[(2-methylbenzoyl)amino]phenyl]-3-[[methyl(phenylmethyl)amino]methyl]-5-oxo-, ethyl ester, monohydrochloride

L4 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN Imidazo[1,2-a]pyrimidine-6-carboxylic acid, 8-[(2,6-difluorophenyl)methyl]-5,8-dihydro-3-[[methyl(phenylmethyl)amino]methyl]-5-oxo-2-[4-[(3-thienylacetyl)amino]phenyl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)





● HCl

RN 229485-19-2 CAPLUS
 CN Imidazo[1,2-a]pyrimidine-6-carboxylic acid, 8-[(2,6-difluorophenyl)methyl]-2-[4-[(ethoxycarbonyl)amino]phenyl]-5,8-dihydro-3-[[methyl(phenylmethyl)amino]methyl]-5-oxo-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 229485-20-5 CAPLUS
 CN Imidazo[1,2-a]pyrimidine-6-carboxylic acid, 8-[(2,6-difluorophenyl)methyl]-5,8-dihydro-3-[[methyl(phenylmethyl)amino]methyl]-5-oxo-2-[4-[(3-thienylcarbonyl)amino]phenyl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 229485-17-0 CAPLUS
 CN Imidazo[1,2-a]pyrimidine-6-carboxylic acid, 8-[(2,6-difluorophenyl)methyl]-5,8-dihydro-2-[4-[(2-methoxybenzoyl)amino]phenyl]-3-[[methyl(phenylmethyl)amino]methyl]-5-oxo-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 229485-18-1 CAPLUS
 CN Imidazo[1,2-a]pyrimidine-6-carboxylic acid, 8-[(2,6-difluorophenyl)methyl]-

L4 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




● HCl

RN 229485-21-6 CAPLUS
 CN Imidazo[1,2-a]pyrimidine-6-carboxylic acid, 8-[(2,6-difluorophenyl)methyl]-5,8-dihydro-3-[[methyl(phenylmethyl)amino]methyl]-2-[4-[(2-naphthalenylcarbonyl)amino]phenyl]-5-oxo-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 229485-22-7 CAPLUS
 CN Imidazo[1,2-a]pyrimidine-6-carboxylic acid, 8-[(2,6-difluorophenyl)methyl]-5,8-dihydro-3-[[methyl(phenylmethyl)amino]methyl]-5-oxo-2-[4-[(3-pyridinylcarbonyl)amino]phenyl]-, ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 229485-23-8 CAPLUS
 CN Imidazo[1,2-a]pyrimidine-6-carboxylic acid, 8-[(2,6-difluorophenyl)methyl]-5,8-dihydro-3-[[methyl(phenylmethyl)amino]methyl]-5-oxo-2-[4-[[tricyclo[3.3.1.1.3,7]dec-1-ylcarbonyl]amino]phenyl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 229485-24-9 CAPLUS
 CN Imidazo[1,2-a]pyrimidine-6-carboxylic acid, 8-[(2,6-difluorophenyl)methyl]-5,8-dihydro-3-[[methyl(phenylmethyl)amino]methyl]-5-oxo-2-[4-[(2-thienylsulfonyl)amino]phenyl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 229485-28-3 CAPLUS
 CN Imidazo[1,2-a]pyrimidine-6-carboxylic acid, 2-[4-((cyclopropylcarbonyl)amino)phenyl]-8-[(2,6-difluorophenyl)methyl]-5,8-dihydro-3-[[methyl(phenylmethyl)amino]methyl]-5-oxo-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 229485-30-7 CAPLUS
 CN Imidazo[1,2-a]pyrimidine-6-carboxylic acid, 8-[(2,6-difluorophenyl)methyl]-5,8-dihydro-3-[[methyl(phenylmethyl)amino]methyl]-2-[4-[[4-methylphenyl)sulfonyl]amino]phenyl]-5-oxo-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 229485-25-0 CAPLUS
 CN Imidazo[1,2-a]pyrimidine-6-carboxylic acid, 8-[(2,6-difluorophenyl)methyl]-5,8-dihydro-3-[[methyl(phenylmethyl)amino]methyl]-5-oxo-2-[4-[(1H-pyrol-1-yl)sulfonyl]amino]phenyl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 229485-26-1 CAPLUS
 CN Imidazo[1,2-a]pyrimidine-6-carboxylic acid, 8-[(2,6-difluorophenyl)methyl]-2-[4-[(4-fluorobenzoyl)amino]phenyl]-5,8-dihydro-3-[[methyl(phenylmethyl)amino]methyl]-5-oxo-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 229485-32-9 CAPLUS
 CN Imidazo[1,2-a]pyrimidine-6-carboxylic acid, 8-[(2,6-difluorophenyl)methyl]-5,8-dihydro-3-[[methyl(phenylmethyl)amino]methyl]-5-oxo-2-[4-[(2-furanylcarbonyl)amino]phenyl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 229485-34-1 CAPLUS
 CN Imidazo[1,2-a]pyrimidine-6-carboxylic acid, 8-[(2,6-difluorophenyl)methyl]-2-[4-[(2-furanylcarbonyl)amino]phenyl]-5,8-dihydro-3-[[methyl(phenylmethyl)amino]methyl]-5-oxo-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 229485-35-2 CAPLUS
 CN Imidazo[1,2-a]pyrimidine-6-carboxylic acid, 8-[(2,6-difluorophenyl)methyl]-5,8-dihydro-3-[[methyl(phenylmethyl)amino]methyl]-5-oxo-2-[4-[[[(phenylamino)carbonyl]amino]phenyl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 229485-36-3 CAPLUS
 CN Imidazo[1,2-a]pyrimidine-6-carboxylic acid, 8-[(2,6-difluorophenyl)methyl]-5,8-dihydro-2-[4-[[[(1-methylethyl)amino]carbonyl]amino]phenyl]-3-[[methyl(phenylmethyl)amino]methyl]-5-oxo-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 229485-39-6 CAPLUS
 CN Imidazo[1,2-a]pyrimidine-6-carboxylic acid, 8-[(2,6-difluorophenyl)methyl]-2-[4-[(ethylsulfonyl)amino]phenyl]-5,8-dihydro-3-[[methyl(phenylmethyl)amino]methyl]-5-oxo-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 229485-40-9 CAPLUS
 CN Imidazo[1,2-a]pyrimidine-6-carboxylic acid, 8-[(2,6-difluorophenyl)methyl]-5,8-dihydro-2-[4-[(2-hydroxypropyl)amino]phenyl]-3-[[methyl(phenylmethyl)amino]methyl]-5-oxo-, ethyl ester (9CI) (CA INDEX NAME)




● HCl

RN 229485-37-4 CAPLUS
 CN Imidazo[1,2-a]pyrimidine-6-carboxylic acid, 2-[4-(benzoylamino)phenyl]-8-[[2,6-difluorophenyl)methyl]-5,8-dihydro-3-[[methyl(phenylmethyl)amino]methyl]-5-oxo-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl



RN 229485-38-5 CAPLUS
 CN Imidazo[1,2-a]pyrimidine-6-carboxylic acid, 8-[(2,6-difluorophenyl)methyl]-5,8-dihydro-3-[[methyl(phenylmethyl)amino]methyl]-5-oxo-2-[4-[[1-oxopropyl]amino]phenyl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)





RN 229485-41-0 CAPLUS
 CN Imidazo[1,2-a]pyrimidine-6-carboxylic acid, 8-[(2,6-difluorophenyl)methyl]-5,8-dihydro-3-[[methyl(phenylmethyl)amino]methyl]-5-oxo-2-[4-[[trifluoroacetyl]amino]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)





RN 229485-42-1 CAPLUS
 CN Imidazo[1,2-a]pyrimidine-6-carboxylic acid, 8-[(2,6-difluorophenyl)methyl]-5,8-dihydro-3-[[methyl(phenylmethyl)amino]methyl]-5-oxo-2-[4-[[propyl(trifluoroacetyl)amino]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 229485-43-2 CAPLUS
 CN Imidazo[1,2-a]pyrimidine-6-carboxylic acid, 8-[(2,6-difluorophenyl)methyl]-5,8-dihydro-3-[[methyl(phenylmethyl)amino]methyl]-5-oxo-2-[4-(propylamino)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 229485-44-3 CAPLUS
 CN Imidazo[1,2-a]pyrimidine-6-carboxylic acid, 8-[(2,6-difluorophenyl)methyl]-5,8-dihydro-2-[4-(4-hydroxyphenyl)-3-[[methyl(phenylmethyl)amino]methyl]-5-oxo-, ethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT